<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordOutput xmlns:ns2="local" id="36492"><DrugName>ceftobiprole medocaril</DrugName><DrugNamesKey><Name id="43128390">Adaluzis</Name><Name id="43087333">Mabelio</Name><Name id="42944018">Zevtera</Name><Name id="42825281">ceftobiprole</Name><Name id="42817611">ceftobiprole medocaril</Name></DrugNamesKey><DrugSynonyms><Name><Value>Ro-63-9141</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>Ro-65-5788</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>Ro-63-9141/000</Value><Types><Type>Prodrug</Type></Types></Name><Name><Value>BAL-9141 prodrug, Basilea</Value></Name><Name><Value>BAL-9141</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>ceftobiprole medocaril</Value><Types><Type>USAN</Type><Type>INN</Type></Types></Name><Name><Value>ceftobiprole</Value><Types><Type>USAN</Type><Type>INN</Type></Types></Name><Name><Value>BAL-5788</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>JNJ-30982081</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>Zevtera</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>Mabelio</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>ceftobiprole medocaril sodium</Value></Name><Name><Value>Adaluzis</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>209467-52-7</Value><Types><Type>CAS RN</Type></Types></Name><Name><Value>252188-71-9</Value><Types><Type>CAS RN</Type></Types></Name><Name><Value>376653-43-9</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="26178">F Hoffmann-La Roche AG</CompanyOriginator><CompaniesPrimary><Company id="1074739">Unimedic AB</Company><Company id="18607">Correvio Pharma Corp</Company><Company id="1168485">Patheon UK Ltd</Company><Company id="1063950">Biotoscana International</Company><Company id="1032662">Shenzhen Gosun Pharmaceutical Co Ltd</Company><Company id="1149364">Avir Pharma Inc</Company><Company id="1022379">Hikma Pharmaceuticals plc</Company><Company id="28104">Basilea Pharmaceutica International Ltd</Company></CompaniesPrimary><CompaniesSecondary><Company id="17332">Johnson &amp; Johnson</Company><Company id="26178">F Hoffmann-La Roche AG</Company></CompaniesSecondary><CrossReferences><SourceEntity id="36492" type="Drug"><TargetEntity id="268261" type="siDrug">Ceftobiprole medocaril</TargetEntity></SourceEntity><SourceEntity id="1022379" type="Company"><TargetEntity id="4295897408" type="organizationId">Hikma Pharmaceuticals PLC</TargetEntity></SourceEntity><SourceEntity id="1032662" type="Company"><TargetEntity id="5000536522" type="organizationId">Shenzhen China Resources Gosun Pharmaceutical Co Ltd</TargetEntity></SourceEntity><SourceEntity id="1063950" type="Company"><TargetEntity id="5036193968" type="organizationId">Biotoscana Farma SA</TargetEntity></SourceEntity><SourceEntity id="1074739" type="Company"><TargetEntity id="4297719914" type="organizationId">Unimedic AB</TargetEntity></SourceEntity><SourceEntity id="1149364" type="Company"><TargetEntity id="5056404912" type="organizationId">Avir Pharma Inc</TargetEntity></SourceEntity><SourceEntity id="1168485" type="Company"><TargetEntity id="4298158910" type="organizationId">Patheon UK Ltd</TargetEntity></SourceEntity><SourceEntity id="17332" type="Company"><TargetEntity id="4295904341" type="organizationId">Johnson &amp; Johnson</TargetEntity></SourceEntity><SourceEntity id="18607" type="Company"><TargetEntity id="4295861998" type="organizationId">Cardiome Pharma Corp</TargetEntity></SourceEntity><SourceEntity id="26178" type="Company"><TargetEntity id="5000075049" type="organizationId">F Hoffmann La Roche AG</TargetEntity></SourceEntity><SourceEntity id="28104" type="Company"><TargetEntity id="5035524212" type="organizationId">Basilea Pharmaceutica International AG</TargetEntity></SourceEntity><SourceEntity id="1267" type="ciIndication"><TargetEntity id="041.12" type="ICD9"></TargetEntity><TargetEntity id="813" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1815" type="ciIndication"><TargetEntity id="J15" type="ICD10"></TargetEntity><TargetEntity id="10060946" type="MEDDRA"></TargetEntity><TargetEntity id="D018410" type="MeSH"></TargetEntity><TargetEntity id="-2031977293" type="omicsDisease"></TargetEntity><TargetEntity id="928" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="308" type="ciIndication"><TargetEntity id="4176" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="40" type="ciIndication"><TargetEntity id="A49.9" type="ICD10"></TargetEntity><TargetEntity id="10060945" type="MEDDRA"></TargetEntity><TargetEntity id="D001424" type="MeSH"></TargetEntity><TargetEntity id="-1693440076" type="omicsDisease"></TargetEntity><TargetEntity id="800" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="485" type="ciIndication"><TargetEntity id="D017192" type="MeSH"></TargetEntity></SourceEntity><SourceEntity id="790" type="ciIndication"><TargetEntity id="10056340" type="MEDDRA"></TargetEntity><TargetEntity id="D017719" type="MeSH"></TargetEntity><TargetEntity id="-1424289263" type="omicsDisease"></TargetEntity><TargetEntity id="495" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1594" type="Action"><TargetEntity id="4457" type="Mechanism">Drugs Targeting Staphylococcus aureus Proteins</TargetEntity><TargetEntity id="3697" type="Mechanism">Drugs Targeting Escherichia coli Proteins</TargetEntity><TargetEntity id="5353" type="Mechanism">Drugs Targeting Clostridium tetani Proteins</TargetEntity><TargetEntity id="5053" type="Mechanism">Anti-Diphtheria Toxin</TargetEntity><TargetEntity id="4493" type="Mechanism">Drugs Targeting Campylobacter jejuni Proteins</TargetEntity><TargetEntity id="3994" type="Mechanism">Drugs Targeting Pseudomonas aeruginosa Proteins</TargetEntity><TargetEntity id="3878" type="Mechanism">Drugs Targeting Bacterial Chaperones</TargetEntity><TargetEntity id="4563" type="Mechanism">Anti-Diphteria Toxin (Corynebacterium diphtheriae)</TargetEntity><TargetEntity id="1060" type="Mechanism">Efflux Pump (Bacterial) Inhibitors</TargetEntity><TargetEntity id="2409" type="Mechanism">Carbon Monoxide-Releasing Agents</TargetEntity><TargetEntity id="5306" type="Mechanism">Drugs Targeting Mycobacterium tuberculosis Proteins</TargetEntity></SourceEntity><SourceEntity id="2953" type="Action"><TargetEntity id="802" type="Mechanism">Mediator Release Inhibitors</TargetEntity><TargetEntity id="775" type="Mechanism">Antiinflammatory Drugs</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="L">Launched</PhaseHighest><PhaseHighestDetailed><FirstLaunched>Bacterial skin infection - Canada - Aug-2008</FirstLaunched></PhaseHighestDetailed><RegulatoryDesignations><RegulatoryDesignation id="2">Fast Track</RegulatoryDesignation><RegulatoryDesignation id="12">Qualified Infectious Disease Product</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication id="1815">Bacterial pneumonia</Indication><Indication id="308">Staphylococcus aureus infection</Indication><Indication id="3779">Infectious endocarditis</Indication><Indication id="485">Bacterial skin infection</Indication></IndicationsPrimary><IndicationsSecondary><Indication id="1267">MRSA infection</Indication><Indication id="313">Streptococcus pneumoniae infection</Indication><Indication id="40">Bacterial infection</Indication><Indication id="790">Diabetic foot ulcer</Indication></IndicationsSecondary><ActionsPrimary><Action id="66340">Penicillin binding protein inhibitor</Action></ActionsPrimary><ActionsSecondary><Action id="2953">Anti-inflammatory</Action><Action id="104">Bacterial cell wall synthesis inhibitor</Action><Action id="15187">Systemic dermatological antibacterial product</Action><Action id="1594">Antibacterial</Action><Action id="1537">Cephalosporin</Action></ActionsSecondary><Technologies><Technology id="648">Intravenous formulation</Technology><Technology id="740">Infusion</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="66">Antibiotic</Technology><Technology id="1652">Prodrug</Technology></Technologies><EphmraCodes><Ephmra><Code>J1</Code><Name>SYSTEMIC ANTIBACTERIALS</Name></Ephmra><Ephmra><Code>J1D</Code><Name>CEPHALOSPORINS</Name></Ephmra></EphmraCodes><LastModificationDate>2019-05-08T10:50:30.000Z</LastModificationDate><ChangeDateLast>2019-05-02T00:00:00.000Z</ChangeDateLast><AddedDate>2001-10-22T15:41:25.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="28104" linkType="Company"&gt;Basilea Pharmaceutica&lt;/ulink&gt; has developed and launched ceftobiprole medocaril (Zeftera; Zevtera; JNJ-30982081; Ro-65-5788; BAL-5788; Mabelio; Adaluzis), a water-soluble prodrug of ceftobiprole and a broad-spectrum, iv, fourth-generation cephalosporin. The product is indicated in the EU  for the treatment of hospital-acquired pneumonia (HAP; excluding ventilator-associated pneumonia; VAP) and community-acquired pneumonia (CAP) in adults  [&lt;ulink linkID="1311757" linkType="Reference"&gt;&lt;/ulink&gt;&lt;ulink linkID="1618937" linkType="Reference"&gt;1618937&lt;/ulink&gt;]. In June 2018, Basilea was seeking to outlicense the drug to a partner in the US [&lt;ulink linkID="2049293" linkType="Reference"&gt;2049293&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2013, the antibiotic was approved  under the EU decentralized procedure for the treatment of HAP (excluding  VAP) and CAP [&lt;ulink linkID="1504454" linkType="Reference"&gt;1504454&lt;/ulink&gt;]; in December 2014, the antibiotic was launched in Germany [&lt;ulink linkID="1618635" linkType="Reference"&gt;1618635&lt;/ulink&gt;]; by June 2015, the drug had been launched in Austria [&lt;ulink linkID="1672179" linkType="Reference"&gt;1672179&lt;/ulink&gt;]. In March 2016, Basilea noted that ceftobiprole would be launched in Europe on a rolling basis, following completion of pricing and reimbursement negotiations [&lt;ulink linkID="1745094" linkType="Reference"&gt;1745094&lt;/ulink&gt;]; by the end of 2017, licensee  &lt;ulink linkID="18607" linkType="Company"&gt;Correvio Pharma&lt;/ulink&gt;   (formerly Cardiome Pharma) was presumably marketing the drug in several European countries [&lt;ulink linkID="2008403" linkType="Reference"&gt;2008403&lt;/ulink&gt;], [&lt;ulink linkID="2034219" linkType="Reference"&gt;2034219&lt;/ulink&gt;]. By December 2017, licensee &lt;ulink linkID="1074739" linkType="Company"&gt;Unimedic&lt;/ulink&gt; had launched the drug in Nordic countries [&lt;ulink linkID="2008403" linkType="Reference"&gt;2008403&lt;/ulink&gt;].  In January 2012, the company  was finalizing its filing plans for the US following discussions with the FDA, and was continuing plans for approval in both pneumonia and skin infections [&lt;ulink linkID="1252443" linkType="Reference"&gt;1252443&lt;/ulink&gt;]; in June 2014, the FDA confirmed that further phase III trials, including prospective CAP and HAP data, would be required for approval [&lt;ulink linkID="1572701" linkType="Reference"&gt;1572701&lt;/ulink&gt;]. In February 2018, the acute bacterial skin and skin structure infections (ABSSSI) trial was initiated   [&lt;ulink linkID="2007699" linkType="Reference"&gt;2007699&lt;/ulink&gt;].  In June 2018, a phase III trial in patients with complicated Staphylococcus aureus bacteremia including infective endocarditis was initiated under a Special Protocol Assessment (SPA) [&lt;ulink linkID="2145763" linkType="Reference"&gt;2145763&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Ceftobiprole was previously launched in Canada by former licensee &lt;ulink linkID="17332" linkType="Company"&gt;Johnson &amp;amp; Johnson&lt;/ulink&gt; in August 2008 for the treatment of complicated skin and skin structure infections (cSSSI), including diabetic foot infections [&lt;ulink linkID="1074945" linkType="Reference"&gt;1074945&lt;/ulink&gt;]; however in April 2010, the drug was withdrawn from the Canadian market following concerns identified in US and European applications [&lt;ulink linkID="1089203" linkType="Reference"&gt;1089203&lt;/ulink&gt;]. An MAA for cSSSI was accepted for review by the EMA in July 2007 [&lt;ulink linkID="813854" linkType="Reference"&gt;813854&lt;/ulink&gt;]; however the authorization process was halted  in February 2009 pending inspections [&lt;ulink linkID="986204" linkType="Reference"&gt;986204&lt;/ulink&gt;].  The CHMP adopted a negative opinion in February 2010  after the inspection   raised concerns over the reliability of the data supporting the MAA [&lt;ulink linkID="1076240" linkType="Reference"&gt;1076240&lt;/ulink&gt;]. In June 2010, the CHMP adopted a final negative opinion [&lt;ulink linkID="1110791" linkType="Reference"&gt;1110791&lt;/ulink&gt;]. In November 2008, the FDA issued a Complete Response Letter regarding the NDA for cSSSI, indicating that it could not approve the NDA  because of a failure to ensure the proper monitoring of clinical trial sites [&lt;ulink linkID="966636" linkType="Reference"&gt;966636&lt;/ulink&gt;], [&lt;ulink linkID="966771" linkType="Reference"&gt;966771&lt;/ulink&gt;], [&lt;ulink linkID="796632" linkType="Reference"&gt;796632&lt;/ulink&gt;]. A second Complete Response Letter was issued by the FDA in December 2009, requesting additional clinical studies in cSSSI [&lt;ulink linkID="1065953" linkType="Reference"&gt;1065953&lt;/ulink&gt;].   In February 2011, J&amp;amp;J returned rights to the drug to Basilea [&lt;ulink linkID="1167274" linkType="Reference"&gt;1167274&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;By September 2008, a phase III trial in febrile neutropenia had been suspended and the comparator was being re-evaluated because of the FDA Medwatch on &lt;ulink linkID="2736" linkType="Drug"&gt;cefepime&lt;/ulink&gt; [&lt;ulink linkID="940801" linkType="Reference"&gt;940801&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><PatentsAndGenerics><displayLabel>Patents and Generics</displayLabel><value>&lt;PatentsAndGenerics&gt;&lt;para&gt;&lt;ulink linkID="IN2742087" linkType="Patent"&gt;WO-09965920&lt;/ulink&gt; covers the ceftobiprole medocaril product; the granted US equivalent, &lt;ulink linkID="PA3109072" linkType="Patent"&gt;US-06232306&lt;/ulink&gt;, is due to expire in May 2019, and the granted European equivalent &lt;ulink linkID="PA3412639" linkType="Patent"&gt;EP-01087980&lt;/ulink&gt;  is due to expire in June 2019, with expiry in June 2024 in certain EU countries following SPC approval. In March 2018, Basilea noted that the Qualified Infectious Disease Product (QIDP) granted designation extended market exclusivity of the drug to 10 years from the date of a potential US approval [&lt;ulink linkID="2015656" linkType="Reference"&gt;2015656&lt;/ulink&gt;].&lt;/para&gt;&lt;/PatentsAndGenerics&gt;</value></PatentsAndGenerics><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;&lt;subtitle&gt;The US&lt;/subtitle&gt;&lt;subtitle&gt;Pneumonia&lt;/subtitle&gt;In August 2015, the FDA granted the drug QIDP status for CAP [&lt;ulink linkID="1685781" linkType="Reference"&gt;1685781&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In January 2012, Basilea was to finalize its US filing plans for pneumonia following further discussions with the FDA [&lt;ulink linkID="1252443" linkType="Reference"&gt;1252443&lt;/ulink&gt;]. In June 2014, the FDA confirmed that further phase III trials, providing prospective community and HAP data, would be required for approval for pneumonia. At that time, Basilea did not intend to conduct further trials without a US partner [&lt;ulink linkID="1572701" linkType="Reference"&gt;1572701&lt;/ulink&gt;]. in October 2015, Basilea planned to discuss the design of a phase III program for  CABP with the FDA; at that time, the company believed that two cross-supportive phase III studies in CABP and ABSSSI would be sufficient to obtain regulatory approval in the US [&lt;ulink linkID="1704441" linkType="Reference"&gt;1704441&lt;/ulink&gt;]. In December 2015, Basilea was preparing phase III protocols for cross-supportive studies for CABP and bacteremia, including endocarditis, for submission to the FDA in 1Q16, seeking SPAs [&lt;ulink linkID="1723896" linkType="Reference"&gt;1723896&lt;/ulink&gt;]. In April 2016, Basilea intended to submit protocols of NDA-supporting phase III trials, including CABP to the FDA with an SPA agreement [&lt;ulink linkID="1753308" linkType="Reference"&gt;1753308&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Skin infections&lt;/subtitle&gt;In December 2017, the FDA granted QIDP designation for the treatment of bacterial bloodstream infections (bacteremia) caused by Staphylococcus aureus [&lt;ulink linkID="1993143" linkType="Reference"&gt;1993143&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2008, the FDA issued an approvable letter for an NDA for ceftobiprole for the treatment of cSSSI, including diabetic foot infections, which had been filed and accepted for review in May and July 2007, respectively [&lt;ulink linkID="887224" linkType="Reference"&gt;887224&lt;/ulink&gt;], [&lt;ulink linkID="796632" linkType="Reference"&gt;796632&lt;/ulink&gt;], [&lt;ulink linkID="813854" linkType="Reference"&gt;813854&lt;/ulink&gt;]. In September 2008, the FDA accepted Basilea's Complete Response for review  [&lt;ulink linkID="943082" linkType="Reference"&gt;943082&lt;/ulink&gt;]. However, in November 2008, the FDA issued a Complete Response Letter indicating that it could not approve the NDA   and asked J&amp;amp;JPRD to conduct extra audit work for its clinical trial sites,  address certain questions relating to the monitoring of the sites and  resolve specific deficiencies of study conduct, after it found that there was a failure to ensure the proper monitoring of the STRAUSS 1 and STRAUSS 2 phase III trials for the drug. The FDA was  only expected to review the submitted clinical data once the data integrity issues  had been resolved [&lt;ulink linkID="966771" linkType="Reference"&gt;966771&lt;/ulink&gt;], [&lt;ulink linkID="966636" linkType="Reference"&gt;966636&lt;/ulink&gt;]. By August 2009, the clinical site inspections requested in the  Complete Response Letter had been completed [&lt;ulink linkID="1033848" linkType="Reference"&gt;1033848&lt;/ulink&gt;], and in September 2009, the FDA accepted J&amp;amp;JPRD's Complete Response submission for review; the agency designated the resubmission as class 2 response [&lt;ulink linkID="1038665" linkType="Reference"&gt;1038665&lt;/ulink&gt;]. However, in December 2009, the FDA issued a second Complete Response Letter, requesting J&amp;amp;JPRD conduct additional clinical studies in cSSSI [&lt;ulink linkID="1065953" linkType="Reference"&gt;1065953&lt;/ulink&gt;]. In October 2015, Basilea planned to discuss the design of a phase III program for ABSSSI with the FDA; at that time, the company believed that two cross-supportive phase III studies in CABP and ABSSSI would be sufficient to obtain regulatory approval in the US [&lt;ulink linkID="1704441" linkType="Reference"&gt;1704441&lt;/ulink&gt;]. In December 2015, Basilea was preparing phase III protocols for cross-supportive studies for ABSSSI, CABP and bacteremia, including endocarditis, for submission to the FDA in 1Q16, seeking SPAs [&lt;ulink linkID="1723896" linkType="Reference"&gt;1723896&lt;/ulink&gt;]. In April 2016, Basilia was working toward agreement of the development plan with the FDA as well as preparing protocols for the three NDA-supporting phase III trials in Staphylococcus aureus bacteremia, CABP and ABSSSI [&lt;ulink linkID="1753308" linkType="Reference"&gt;1753308&lt;/ulink&gt;]. In February 2017, Basilia submitted the clinical study protocols for ABSSSI and Staphylococcus aureus bacteremia to the FDA and planned to initiate  a phase III program mid-2017 following completion of the FDA special protocol assessment process [&lt;ulink linkID="1901935" linkType="Reference"&gt;1901935&lt;/ulink&gt;]. In April 2017, Basilea reached an agreement with the FDA on the SPAs for the two  phase III studies for the treatment of ABSSSI and Staphylococcus aureus bacteremia [&lt;ulink linkID="1919479" linkType="Reference"&gt;1919479&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Basilea received Fast Track status for the treatment of cSSSI, including diabetic foot infections in March 2003 [&lt;ulink linkID="481324" linkType="Reference"&gt;481324&lt;/ulink&gt;]. The company was also awarded Fast Track status for pneumonia in August 2005 [&lt;ulink linkID="619554" linkType="Reference"&gt;619554&lt;/ulink&gt;]. In August 2015, the FDA granted the drug QIDP status for ABSSSIs [&lt;ulink linkID="1685781" linkType="Reference"&gt;1685781&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Europe&lt;/subtitle&gt;&lt;subtitle&gt;Pneumonia&lt;/subtitle&gt;By September 2013, Basilia had filed an MAA with Swissmedic for the treatment of HAP and CAP; at that time, Swissmedic accepted the MAA for review [&lt;ulink linkID="1477276" linkType="Reference"&gt;1477276&lt;/ulink&gt;]. In December 2014, the drug was approved in Switzerland for the treatment in adults of CAP and HAP (excluding VAP) [&lt;ulink linkID="1622429" linkType="Reference"&gt;1622429&lt;/ulink&gt;]. By August 2016, the drug was launched in Switzerland [&lt;ulink linkID="1788011" linkType="Reference"&gt;1788011&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In July 2012, Basilea filed an MAA under the decentralized procedure for use of ceftobiprole for the treatment of hospitalized CAP and HAP  [&lt;ulink linkID="1311757" linkType="Reference"&gt;1311757&lt;/ulink&gt;]; in October 2012, the MAA was accepted for review [&lt;ulink linkID="1328921" linkType="Reference"&gt;1328921&lt;/ulink&gt;]. In October 2013, the drug was approved in  Europe, under the decentralized procedure, for HAP (excluding VAP) and CAP in adults [&lt;ulink linkID="1504454" linkType="Reference"&gt;1504454&lt;/ulink&gt;].  In July 2014, launches in key European markets were planned for 2015 [&lt;ulink linkID="1578621" linkType="Reference"&gt;1578621&lt;/ulink&gt;]. In October 2014, the company received national licenses in Austria, Belgium, Denmark, Finland, France, Germany, Italy, Luxembourg, Norway, Spain, Sweden and the UK for CAP and HAP (excluding VAP)  [&lt;ulink linkID="1607219" linkType="Reference"&gt;1607219&lt;/ulink&gt;]. In December 2014, the antibiotic was launched in Germany [&lt;ulink linkID="1618635" linkType="Reference"&gt;1618635&lt;/ulink&gt;]. By June 2015, the drug had been launched in Austria [&lt;ulink linkID="1672179" linkType="Reference"&gt;1672179&lt;/ulink&gt;].  In March 2015, further regulatory filings were planned under the Repeat Use Procedure. By that time, the antibiotic had been launched in France, Italy and the UK, and launch in Spain was anticipated [&lt;ulink linkID="1641414" linkType="Reference"&gt;1641414&lt;/ulink&gt;], [&lt;ulink linkID="1655454" linkType="Reference"&gt;1655454&lt;/ulink&gt;]. In September 2016, the licensee in Nordic countries, Unimedic, was planning to commericalize the drug in Norway, Iceland, Denmark and Sweden [&lt;ulink linkID="1797653" linkType="Reference"&gt;1797653&lt;/ulink&gt;]; by February 2018, licensee Unimedic had launched the drug in Nordic countries [&lt;ulink linkID="2008403" linkType="Reference"&gt;2008403&lt;/ulink&gt;]. In September 2017, &lt;ulink linkID="18607" linkType="Company"&gt;Cardiome Pharma&lt;/ulink&gt; licensed the drug for commercialization  in  more than 34 countries in Europe (excluding Nordic countries) [&lt;ulink linkID="1961032" linkType="Reference"&gt;1961032&lt;/ulink&gt;], [&lt;ulink linkID="1961529" linkType="Reference"&gt;1961529&lt;/ulink&gt;]; by the end of 2017, the agreement was executed and Cardiome was presumably marketing the drug [&lt;ulink linkID="2008403" linkType="Reference"&gt;2008403&lt;/ulink&gt;]; by December 2017, the drug had been approved in Ireland as Adaluzis [&lt;ulink linkID="2015656" linkType="Reference"&gt;2015656&lt;/ulink&gt;]. In May 2018, launch occurred in Spain [&lt;ulink linkID="2034219" linkType="Reference"&gt;2034219&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Skin infections&lt;/subtitle&gt;In October 2007, Swissmedic accepted an MAA for the treatment of cSSSI, including diabetic foot infections, for review [&lt;ulink linkID="837278" linkType="Reference"&gt;837278&lt;/ulink&gt;]. In November 2008, ceftobiprole medocaril was approved in Switzerland, and by February 2009, launch had taken place [&lt;ulink linkID="962759" linkType="Reference"&gt;962759&lt;/ulink&gt;], [&lt;ulink linkID="962772" linkType="Reference"&gt;962772&lt;/ulink&gt;],  [&lt;ulink linkID="986214" linkType="Reference"&gt;986214&lt;/ulink&gt;]. In September 2010, Cilag requested the withdrawal of the marketing authorization for ceftobiprole medocaril in Switzerland for cSSSI, and would discontinue sale of the drug following negative reviews of regulatory filings in the US and EU [&lt;ulink linkID="1129434" linkType="Reference"&gt;1129434&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;An accelerated assessment was granted for cSSSI in May 2007 [&lt;ulink linkID="805391" linkType="Reference"&gt;805391&lt;/ulink&gt;], [&lt;ulink linkID="800129" linkType="Reference"&gt;800129&lt;/ulink&gt;];  the MAA  was filed in June 2007 [&lt;ulink linkID="805391" linkType="Reference"&gt;805391&lt;/ulink&gt;]. The MAA was accepted for review in July 2007 and in November 2008, the EU CHMP issued a positive opinion [&lt;ulink linkID="813854" linkType="Reference"&gt;813854&lt;/ulink&gt;], [&lt;ulink linkID="965560" linkType="Reference"&gt;965560&lt;/ulink&gt;]. In February 2009, the EC decision process was delayed pending the completion of a good clinical practice (GCP) inspection [&lt;ulink linkID="986204" linkType="Reference"&gt;986204&lt;/ulink&gt;], [&lt;ulink linkID="986215" linkType="Reference"&gt;986215&lt;/ulink&gt;], [&lt;ulink linkID="986214" linkType="Reference"&gt;986214&lt;/ulink&gt;]. By August 2009, the GCP inspection had been completed    [&lt;ulink linkID="1033848" linkType="Reference"&gt;1033848&lt;/ulink&gt;]. In February 2010, the CHMP issued a negative opinion, stating that inspections showed that the phase III studies supporting the MAA had not been conducted in compliance with GCP in some sites, which raised concerns over the reliability of the data [&lt;ulink linkID="1076240" linkType="Reference"&gt;1076240&lt;/ulink&gt;]. In March 2010, Janssen-Cilag submitted a request for re-examination of the negative opinion adopted by the CHMP [&lt;ulink linkID="1081392" linkType="Reference"&gt;1081392&lt;/ulink&gt;]; in June 2010, the CHMP confirmed its previous negative opinion after re-examination, and recommended against approval of ceftobiprole medocaril [&lt;ulink linkID="1110791" linkType="Reference"&gt;1110791&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Japan&lt;/subtitle&gt;In June 2009, a potential filing was expected in Japan by 2013 [&lt;ulink linkID="1016783" linkType="Reference"&gt;1016783&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;China&lt;/subtitle&gt;In June 2009, potential filings were expected in China by 2013 [&lt;ulink linkID="1016783" linkType="Reference"&gt;1016783&lt;/ulink&gt;]. In December 2018, a filing for approval was submitted in China [&lt;ulink linkID="2100481" linkType="Reference"&gt;2100481&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Rest of the world&lt;/subtitle&gt;&lt;subtitle&gt;Canada&lt;/subtitle&gt;In October 2015, the antibiotic was approved in Canada for the treatment of adult patients aged 18 years and older with bacterial lung infections, including   HAP, excluding  VAP, and for the treatment of  CAP [&lt;ulink linkID="1702266" linkType="Reference"&gt;1702266&lt;/ulink&gt;]. In April 2018, licensee &lt;ulink linkID="1149364" linkType="Company"&gt;Avir Pharma&lt;/ulink&gt; launched the drug in Canada [&lt;ulink linkID="2020325" linkType="Reference"&gt;2020325&lt;/ulink&gt;], [&lt;ulink linkID="2021044" linkType="Reference"&gt;2021044&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;An NDS for cSSSI had been filed with Health Canada in July 2007 [&lt;ulink linkID="813560" linkType="Reference"&gt;813560&lt;/ulink&gt;]; approval was granted in June 2008 [&lt;ulink linkID="921274" linkType="Reference"&gt;921274&lt;/ulink&gt;]. Ceftobiprole was launched in Canada for the treatment of cSSSI, including diabetic foot infection, in August 2008 [&lt;ulink linkID="1074945" linkType="Reference"&gt;1074945&lt;/ulink&gt;]. In April 2010, Janssen-Ortho discontinued the sale of ceftobiprole for cSSSI following the failure of marketing applications for cSSSI in the US and EU due to concerns over clinical data. The company noted that  the discontinuation did not preclude the submission of a new marketing application in future [&lt;ulink linkID="1089203" linkType="Reference"&gt;1089203&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Latin America&lt;/subtitle&gt;In March 2015, Basilea noted that the company was  seeking regulatory approval in South America [&lt;ulink linkID="1641414" linkType="Reference"&gt;1641414&lt;/ulink&gt;]. By December 2017, the drug had been approved in Argentina for the treatment of CAP and HAP, excluding VAP. In March 2018, the drug was launched in Argentina by &lt;ulink linkID="1063950" linkType="Company"&gt;Grupo Biotoscana&lt;/ulink&gt; [&lt;ulink linkID="2010630" linkType="Reference"&gt;2010630&lt;/ulink&gt;], [&lt;ulink linkID="2015656" linkType="Reference"&gt;2015656&lt;/ulink&gt;]. In August 2018, the drug was approved in Peru [&lt;ulink linkID="2063306" linkType="Reference"&gt;2063306&lt;/ulink&gt;]; by March 2019, the drug had been launched in Peru [&lt;ulink linkID="2136234" linkType="Reference"&gt;2136234&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Middle East and Africa&lt;/subtitle&gt;By December 2017, the drug had been a approved in Saudi Arabia [&lt;ulink linkID="2015656" linkType="Reference"&gt;2015656&lt;/ulink&gt;]. In May 2018, licensee &lt;ulink linkID="1164410" linkType="Company"&gt;Hikma Pharmaceuticals LLC&lt;/ulink&gt; launched ceftobiprole in Saudi Arabia. At that time, launches in other Middle East and North African countries were planned [&lt;ulink linkID="2033845" linkType="Reference"&gt;2033845&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By August 2016, Hikma Pharmaceuticals had submitted the first filing in an undisclosed country in the Middle East and North Africa (MENA) region [&lt;ulink linkID="1788588" linkType="Reference"&gt;1788588&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Commonwealth of Independent States&lt;/subtitle&gt;By December 2009, the drug had been approved in Russia [&lt;ulink linkID="1065953" linkType="Reference"&gt;1065953&lt;/ulink&gt;]. However, by September 2010, J&amp;amp;JPRD had submitted requests for withdrawal of the  marketing authorization for ceftobiprole in  Russia, and sale of the drug was to be discontinued following negative reviews of regulatory filings in the US and EU [&lt;ulink linkID="1129434" linkType="Reference"&gt;1129434&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By December 2009, the drug had been approved in Azerbaijan [&lt;ulink linkID="1065953" linkType="Reference"&gt;1065953&lt;/ulink&gt;]. However, by September 2010, J&amp;amp;JPRD had submitted requests for withdrawal of the  marketing authorization for ceftobiprole in Azerbaijan, and sale of the drug was to be discontinued following negative reviews of regulatory filings in the US and EU [&lt;ulink linkID="1129434" linkType="Reference"&gt;1129434&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2008, the drug was approved in Ukraine [&lt;ulink linkID="986204" linkType="Reference"&gt;986204&lt;/ulink&gt;]; by April 2009, it had been launched  [&lt;ulink linkID="1004851" linkType="Reference"&gt;1004851&lt;/ulink&gt;].  However, by September 2010, J&amp;amp;JPRD had submitted requests for withdrawal of the  marketing authorization for ceftobiprole in  Ukraine, and sale of the drug was to be discontinued following negative reviews of regulatory filings in the US and EU [&lt;ulink linkID="1129434" linkType="Reference"&gt;1129434&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;South Asia&lt;/subtitle&gt;In June 2009, a potential filing was expected in India by 2013 [&lt;ulink linkID="1016783" linkType="Reference"&gt;1016783&lt;/ulink&gt;]. In March 2015, Basilea noted that the company was  seeking regulatory approval in Asia [&lt;ulink linkID="1641414" linkType="Reference"&gt;1641414&lt;/ulink&gt;]&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Asia Pacific&lt;/subtitle&gt;By December 2009, the drug had been approved in Hong Kong for cSSSI [&lt;ulink linkID="1065953" linkType="Reference"&gt;1065953&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;By October 2007, the drug was undergoing regulatory review in Australia for the treatment of cSSSI [&lt;ulink linkID="837122" linkType="Reference"&gt;837122&lt;/ulink&gt;]; in March 2015, Basilea noted that the company was still seeking regulatory approval in Australia [&lt;ulink linkID="1641414" linkType="Reference"&gt;1641414&lt;/ulink&gt;]. In November 2015, the drug was  in Australia for the treatment of HAP including VAP, and CAP [&lt;ulink linkID="1736265" linkType="Reference"&gt;1736265&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;&lt;subtitle&gt;Complicated skin and skin structure infections&lt;/subtitle&gt;In May 2017, a randomized, double-blind, parallel-group-assignment, quadruple-masked, multicenter, phase III trial (&lt;ulink linkID="297036" linkType="Protocol"&gt;NCT03138733&lt;/ulink&gt;; BPR-CS-009 )  was planned to compare the efficacy and safety of ceftobiprole medocaril versus &lt;ulink linkID="2911" linkType="Drug"&gt;daptomycin&lt;/ulink&gt; in patients (expected n = 390) with complicated Staphylococcus aureus bacteremia. Th eprimary endpoint was a comparison of overall success rates in the modified intent-to-treat population. At that time, the trial was expected to complete in February 2020    [&lt;ulink linkID="1993231" linkType="Reference"&gt;1993231&lt;/ulink&gt;]. In December 2017, the phase III trial  for the treatment of adult patients with Staphylococcus aureus bacteremia was expected to initiate in 1H18 [&lt;ulink linkID="1993143" linkType="Reference"&gt;1993143&lt;/ulink&gt;]. In August 2018, the trial was initiated [&lt;ulink linkID="2061544" linkType="Reference"&gt;2061544&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In February 2017, Basilea planned to initiate  a phase III clinical program in the US under a &lt;ulink linkID="1042246" linkType="Company"&gt;Biomedical Advanced Research and Development Authority&lt;/ulink&gt; (BARDA) contract in  mid-2017 for ABSSSI [&lt;ulink linkID="1901935" linkType="Reference"&gt;1901935&lt;/ulink&gt;]. In April 2017, a SPA agreed, multicenter, double-blind, randomized, non-inferiority, phase III trial  was planned to compare ceftobiprole with &lt;ulink linkID="44401" linkType="Drug"&gt;vancomycin&lt;/ulink&gt; and &lt;ulink linkID="51816" linkType="Drug"&gt;aztreonam&lt;/ulink&gt; for the treatment of adults with ABSSSI. The FDA-agreed primary endpoint was early clinical response at 48 to 72 h after start of treatment [&lt;ulink linkID="1919479" linkType="Reference"&gt;1919479&lt;/ulink&gt;]. In May 2017, the phase III trial (&lt;ulink linkID="297070" linkType="Protocol"&gt;NCT03137173&lt;/ulink&gt;; BPR-CS-008)  was not yet recruiting patients (expected n = 674) with ABSSSI. At that time, the trial was expected to complete in January 2019  [&lt;ulink linkID="1993229" linkType="Reference"&gt;1993229&lt;/ulink&gt;]. In February 2018, patient enrollment commenced [&lt;ulink linkID="2007699" linkType="Reference"&gt;2007699&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2016, data from a post-hoc analysis of patients with staphylococcal bacteremia from four randomized, double-blind, phase III studies for cSSSI were presented at the 26th ECCMID in Amsterdam, the Netherlands. The clinical responses in ceftobiprole-treated patients were similar to those treated with standard-of-care comparators, with a trend towards lower 30-day all-cause mortality in the ceftobiprole arm [&lt;ulink linkID="1751941" linkType="Reference"&gt;1751941&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In January 2014, a clinical trial application was filed in China, presumed to be  for  bacterial skin infections [&lt;ulink linkID="1513655" linkType="Reference"&gt;1513655&lt;/ulink&gt;], [&lt;ulink linkID="1517757" linkType="Reference"&gt;1517757&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2007, data from a phase III trial for diabetic foot infections were presented at the 45th annual meeting of the Infectious Disease Society of America in San Diego, CA. In the multicenter, double-blind study, 257 patients with mild, moderate and severe infections (27, 59 and 13%, respectively) received 500 mg of iv ceftobiprole every 8 hours, or 1 g of iv &lt;ulink linkID="44401" linkType="Drug"&gt;vancomycin&lt;/ulink&gt; every 12 h plus 1 g of iv &lt;ulink linkID="44317" linkType="Drug"&gt;ceftazidime&lt;/ulink&gt; every 8 h. Of the 257 patients, 67% were microbiologically evaluable. A total of 86.2% of patients who received ceftobiprole were cured, compared with 81.8% of patients on vancomycin plus ceftazidime. Ceftobiprole was well tolerated and the incidence of adverse events in ceftobiprole-treated patients was similar to those observed in patients treated with vancomycin plus ceftazidime [&lt;ulink linkID="837122" linkType="Reference"&gt;837122&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In September 2007, combined clinical data on ceftobiprole from STRAUSS I and STRAUSS II were presented at the 47th ICAAC meeting in Chicago, IL. Data from the two trials showed Panton-Valentine leukocidin (PVL)-positive MRSA and methicillin-sensitive Staphylococcus aureus (MSSA) were the leading cause of cSSSI in the pooled study experience. The clinical cure rate in ceftobiprole-treated patients with PVL-positive S aureus infection was greater than 90% [&lt;ulink linkID="829873" linkType="Reference"&gt;829873&lt;/ulink&gt;]. An analysis of the relationship between a pharmacokinetic/pharmacodynamic parameter and therapeutic response of ceftobiprole cSSSI patients demonstrated that there was a strong association between achieving greater than 30% or greater than 50% T&amp;gt;MIC targets and the probability of achieving clinical or microbiological success with ceftobiprole [&lt;ulink linkID="828392" linkType="Reference"&gt;828392&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;STRAUSS II (&lt;ulink linkID="8728" linkType="Protocol"&gt;NCT00210899&lt;/ulink&gt;; BAP0414) was the second pivotal phase III trial to be conducted by Basilea and J&amp;amp;J, and was initiated in October 2005 to investigate medocaril for the treatment of both Gram-positive and Gram-negative bacterial infections, including diabetic foot infections [&lt;ulink linkID="628051" linkType="Reference"&gt;628051&lt;/ulink&gt;]. The double-blind study recruited 828 patients, including subjects with diabetic foot and MRSA infections, and compared ceftobiprole to ceftazidime/vancomycin combination therapy. The trial was completed in October 2006 and results were reported in January 2007. Overall, ceftobiprole produced a 91% cure rate, compared to a 90% cure rate with the combination therapy. In subjects with diabetic foot infections, the cure rate was 86% for ceftobiprole and 82% for ceftazidime/vancomycin. Ceftobiprole cured 91% of MRSA cases, compared to 86% for the combination regimen. Both regimens produced an 84% cure rate against Gram-negative pathogens. Ceftobiprole was well tolerated and adverse events were comparable between the two treatment groups [&lt;ulink linkID="756798" linkType="Reference"&gt;756798&lt;/ulink&gt;], [&lt;ulink linkID="940829" linkType="Reference"&gt;940829&lt;/ulink&gt;]. Similar data were presented at the 47th ICAAC meeting in Chicago, IL, in September 2007. A microbiological eradication rate of 88% was reported for ceftobiprole and 89% for ceftazidime/vancomycin [&lt;ulink linkID="829876" linkType="Reference"&gt;829876&lt;/ulink&gt;], [&lt;ulink linkID="829877" linkType="Reference"&gt;829877&lt;/ulink&gt;], [&lt;ulink linkID="831378" linkType="Reference"&gt;831378&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;The STRAUSS I study (&lt;ulink linkID="9091" linkType="Protocol"&gt;NCT00228982&lt;/ulink&gt;; BAP0154) was initiated in November 2004 to evaluate ceftobiprole versus vancomycin in 700 patients recruited from over 100 centers worldwide. The primary efficacy endpoint was clinical outcome at the test-of-cure visit, which occurred between 7 to 14 days after end of therapy [&lt;ulink linkID="569097" linkType="Reference"&gt;569097&lt;/ulink&gt;]. By October 2005, enrollment in STRAUSS was complete and the study  was completed the following month [&lt;ulink linkID="628051" linkType="Reference"&gt;628051&lt;/ulink&gt;], [&lt;ulink linkID="940832" linkType="Reference"&gt;940832&lt;/ulink&gt;]. In March 2006, Basilea reported that non-inferiority had been demonstrated; 93.3% of patients were cured with ceftobiprole, compared to 93.5% of vancomycin-treated patients. In addition, the ceftobiprole response rate in MRSA infections was 91.9%, compared with 90.0% for vancomycin. Adverse events were comparable between the two groups [&lt;ulink linkID="653592" linkType="Reference"&gt;653592&lt;/ulink&gt;]. In April 2006, these data were presented at the 16th ECCMID in Nice, France [&lt;ulink linkID="662172" linkType="Reference"&gt;662172&lt;/ulink&gt;], and in September 2006, similar data were also presented at the 46th ICAAC meeting in San Francisco, CA [&lt;ulink linkID="687138" linkType="Reference"&gt;687138&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2004, Basilea reported positive phase II results from a study (BAP0034) in patients with cSSSIs requiring surgical intervention. Ceftobiprole cured all 35 evaluable patients, with clinical improvement observed within the first days of treatment. No treatment failures occurred and the safety of ceftobiprole was consistent with the established safety profile of the cephalosporin class, with mild-to-moderate nausea reported as the most frequent side effect [&lt;ulink linkID="526085" linkType="Reference"&gt;526085&lt;/ulink&gt;]. In October 2004, further results from BAP0034, were presented at the 44th ICAAC meeting in Washington, DC. Ceftobiprole 750 mg was administered as a twice-daily, 30-minute iv-infusion for 7 to 14 days, extendable to 21 days. Of the 40 patients enrolled, 35 were clinically evaluable and were considered clinically cured and 23 were microbiologically evaluable, of which 21 were considered cured (ie their infection was undetectable). All pathogens, mainly Staphylococcus and Streptococcus spp, but also including Enterococci, Acinetobacter spp, Burkholderia cepacia and Proteus vulgaris, were sensitive to ceftobiprole and no increase in resistance during therapy was observed [&lt;ulink linkID="568088" linkType="Reference"&gt;568088&lt;/ulink&gt;]. In April 2006, these data were presented at the 16th ECCMID in Nice, France [&lt;ulink linkID="662172" linkType="Reference"&gt;662172&lt;/ulink&gt;] and in September 2006, similar data were also presented at the 46th ICAAC meeting in San Francisco, CA [&lt;ulink linkID="689610" linkType="Reference"&gt;689610&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Community-acquired pneumonia&lt;/subtitle&gt;In July 2009, phase III development for this indication was ongoing [&lt;ulink linkID="1032235" linkType="Reference"&gt;1032235&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In July 2007, a phase III trial (&lt;ulink linkID="14074" linkType="Protocol"&gt;NCT00326287&lt;/ulink&gt;) was completed on schedule in patients hospitalized with CAP. The randomized, double-blind, placebo-controlled, parallel-group, safety and efficacy trial was expected to enroll 670 patients [&lt;ulink linkID="942251" linkType="Reference"&gt;942251&lt;/ulink&gt;], [&lt;ulink linkID="796914" linkType="Reference"&gt;796914&lt;/ulink&gt;] and was initiated in May 2006 [&lt;ulink linkID="668158" linkType="Reference"&gt;668158&lt;/ulink&gt;]. In September 2007, top-line data, presumed to be from this trial, were reported. The trial assessed ceftobiprole versus &lt;ulink linkID="44384" linkType="Drug"&gt;ceftriaxone&lt;/ulink&gt; with or without &lt;ulink linkID="11036" linkType="Drug"&gt;linezolid&lt;/ulink&gt;. The primary endpoint was non-inferiority in clinical cure rate. The data showed that the clinical cure rate in the evaluable population was 86% for ceftobiprole and 87% for the comparator. Microbiological eradication rates were 88% and 92% in the two groups, respectively. The cure rate for patients with moderate-to-severe pneumonia (defined as a score &amp;gt; 90 on the PORT pneumonia severity index) was 89% and 81% for ceftobiprole and comparator, respectively. Ceftobiprole was well tolerated and had an adverse event profile consistent with that previously reported [&lt;ulink linkID="830686" linkType="Reference"&gt;830686&lt;/ulink&gt;]. A more detailed analysis of the top-line results demonstrating high-cure rates in patients at risk of poor outcomes was presented in May 2008 at the International Conference of the American Thoracic Society (ATS) in Toronto, Canada [&lt;ulink linkID="942347" linkType="Reference"&gt;942347&lt;/ulink&gt;]. In September 2014, post-hoc analysis data from patients enrolled in China, South Korea and Taiwan were presented at the 54th ICAAC Meeting in Washington, DC. Ceftobiprole was well tolerated and associated with clinical cure and microbiological eradication rates of 73.5 and 92.9%, respectively, compared with 70.4 and 80.0% for ceftriaxone, respectively  [&lt;ulink linkID="1590461" linkType="Reference"&gt;1590461&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Nosocomial pneumonia&lt;/subtitle&gt;In July 2009, phase III development for this indication was ongoing [&lt;ulink linkID="1032235" linkType="Reference"&gt;1032235&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2007, preliminary results from a phase III trial for nosocomial pneumonia were reported showing that ceftobiprole was non-inferior to ceftazidime plus linezolid. The trial was a consolidated protocol from two previous nosocomial pneumonia trials. Ceftobiprole treatment and ceftazidime plus linezolid cured 69% and 72% of clinically evaluable patients, respectively. When patients with ventilator-associated pneumonia (VAP) were excluded from the results the cure rates were 77% and 76%, respectively. Non-inferiority in the subset of patients with VAP was not established. Ceftobiprole was well tolerated and the rate of adverse events was comparable between the two treatment groups [&lt;ulink linkID="837585" linkType="Reference"&gt;837585&lt;/ulink&gt;]. In September 2014, post-hoc analysis data from patients enrolled in China, South Korea and Taiwan were presented at the 54th ICAAC Meeting in Washington, DC. Ceftobiprole was well tolerated and associated with clinical cure and microbiological eradication rates of 46.3 and 38.9%, respectively, compared with 46.3 and 21.1% for ceftazidime, respectively [&lt;ulink linkID="1590461" linkType="Reference"&gt;1590461&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2007, two phase III trials (&lt;ulink linkID="47173" linkType="Protocol"&gt;NCT00210964&lt;/ulink&gt;; &lt;ulink linkID="11018" linkType="Protocol"&gt;NCT00229008&lt;/ulink&gt;) in nosocomial pneumonia were completed. The randomized, double-blind, placebo-controlled, parallel-group safety and efficacy studies compared ceftobiprole plus placebo with a comparator drug. The primary endpoints were rate of clinical cure. Both trials had an estimated enrollment of 770 patients. NCT00210964 was planned for initiation in March 2005, while NCT00229008 was expected to begin in December 2004 [&lt;ulink linkID="942248" linkType="Reference"&gt;942248&lt;/ulink&gt;], [&lt;ulink linkID="942249" linkType="Reference"&gt;942249&lt;/ulink&gt;]. However, Basilea did not report the initiation of phase III development in this indication until April 2005, when the CHOPIN trial commenced [&lt;ulink linkID="594842" linkType="Reference"&gt;594842&lt;/ulink&gt;], [&lt;ulink linkID="664516" linkType="Reference"&gt;664516&lt;/ulink&gt;]. By March 2008, both studies   had been completed [&lt;ulink linkID="942248" linkType="Reference"&gt;942248&lt;/ulink&gt;], [&lt;ulink linkID="942249" linkType="Reference"&gt;942249&lt;/ulink&gt;]. In April 2013, an analysis of data from a trial presumed to be one of the above was presented at the 23rd European Congress of Clinical Microbiology and Infectious Diseases in Berlin, Germany; results showed that clinical outcome at the test-of-cure visit was associated with exposure to the drug during treatment [&lt;ulink linkID="1411602" linkType="Reference"&gt;1411602&lt;/ulink&gt;]. ​In September 2014, data from a subgroup analysis of the NCT00210964 trial  were presented at the 24th ERS Annual Congress in Munich, Germany.  In the ceftobiprole  group, the clinical cure rate at the test-of-cure visit (primary endpoint) was 52.3, 23, 60 and 57.1%; in the ceftazidime/ linezolid groups, the values were 45.5, 23.5, 53.8 and 35.7% in patients who were in intensive care unit (ICU), patients with baseline bacteremia, Pseudomonas aeruginosa and MRSA, respectively. Clinical improvement at day 4 was seen in 73.9 and 67.6% of ICU patients in the ceftobiprole  and ceftazidime/ linezolid groups, respectively [&lt;ulink linkID="1592405" linkType="Reference"&gt;1592405&lt;/ulink&gt;]. In April 2015, further post-hoc analysis data were presented at the 25th ECCMID in Copenhagen, Denmark.  In the intent-to-treat  analysis, the respective clinical cure rates at test-of-cure visit for ceftobiprole and linezolid + ceftazidime were 60 and 55% in the early onset HAP group and 60 and 60% in the late onset HAP group. Overall, ceftobiprole medocaril was found to be effective, broad-spectrum, bactericidal antibiotic for the empirical treatment of HAP (excluding ventilator-associated pneumonia) [&lt;ulink linkID="1653610" linkType="Reference"&gt;1653610&lt;/ulink&gt;]. In September 2015, results from a post hoc analysis in patients with HAP excluding VAP who were at high risk of poor outcomes or who were severely ill (n = 571) were presented at the 2015 ICAAC/ICC Meeting in San Diego, CA. Clinical cure rates TOC visit were 59.6% in the overall population, 52.3% in patients who received treatment in ICU at baseline, 49.5% in patients with an Acute Physiology And Chronic Health Evaluation II score &amp;gt;/= 15, 61.0% in patients with &amp;gt; 10 comorbidities, 59.0% in patients aged &amp;gt;/= 75 years, 69.7% in patients with chronic obstructive pulmonary disease and 29.2% in patients with bacteremia, respectively, in the ceftobiprole group (respective values in the ceftazidime + linezolid group were 58.8, 45.4, 46.2, 52.2, 56.8, 59.1 and 29.6%). In general, ceftobiprole exhibited good tolerability in the overall patient population as well as in all patient subgroups [&lt;ulink linkID="1692748" linkType="Reference"&gt;1692748&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2015, clinical data were presented from a multicenter, open-label, parallel-group, non-randomized study (&lt;ulink linkID="30575" linkType="Protocol"&gt;NCT00770978&lt;/ulink&gt;)  at the 25th ECCMID in Copenhagen, Denmark.																		Patients (n = 33) were stratified by calculated creatinine clearance (CLcr) and administered iv infusion of ceftobiprole (1000 mg, q12h)  or q8h  over 4 h on day 1. On day 2, 1000 mg ceftobiprole was administered as single dose (4 h) in all groups. In subjects with CLcr &amp;gt;150 mL/min, ceftobiprole systemic clearance was 2-fold greater compared with CLcr &amp;lt; 80 ml/min. AUC and Cmax were inversely related to CLcr and plasma-protein binding was 19 to 22% and not dependent on CLcr [&lt;ulink linkID="1653616" linkType="Reference"&gt;1653616&lt;/ulink&gt;].&lt;br&gt;&lt;/br&gt;&lt;br&gt;&lt;/br&gt;&lt;subtitle&gt;Febrile neutropenia&lt;/subtitle&gt;In September 2007, a randomized, double-blind, parallel-group, safety and efficacy phase III trial (&lt;ulink linkID="8804" linkType="Protocol"&gt;NCT00529282&lt;/ulink&gt;; CR014206; CEFTOFBN3004) was initiated in patients with febrile neutropenia (expected n = 342) at 55 sites worldwide. Patients were to receive ceftobiprole (500 mg every 8 hours via a 120-minute infusion) or &lt;ulink linkID="2736" linkType="Drug"&gt;cefepime&lt;/ulink&gt; (2 g every 8 h via 30-min infusion) with or without vancomycin (1000 mg every 12 h via 60-min infusion) for 7 to 14 days. The primary endpoint of the study was clinical cure rate [&lt;ulink linkID="830686" linkType="Reference"&gt;830686&lt;/ulink&gt;]. The trial was expected to be completed in August 2008, however, by September 2008 the trial had been suspended and the comparator was being re-evaluated because of the FDA Medwatch on cefepime. By April 2009, the study had been discontinued due to administrative reasons  unrelated to safety [&lt;ulink linkID="940801" linkType="Reference"&gt;940801&lt;/ulink&gt;], [&lt;ulink linkID="830686" linkType="Reference"&gt;830686&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Staphylococcus aureus bacteremia&lt;/subtitle&gt;In April 2017, Basilea planned to initiate  a SPA agreed, phase III clinical program in the US under the BARDA contract to evaluate ceftobiprole for the treatment of Staphylococcus aureus bacteremia in  the next  3 to 6 months. Basilea would conduct a multicenter, double-blind, randomized, non-inferiority, phase III trial to compare ceftobiprole with &lt;ulink linkID="2911" linkType="Drug"&gt;daptomycin&lt;/ulink&gt; in the treatment of adult patients with Staphylococcus aureus bacteremia, including infective endocarditis. The FDA-agreed primary endpoint was overall success at a post-treatment visit 70 days after randomization, assessed by an independent Data Review Committee [&lt;ulink linkID="1919479" linkType="Reference"&gt;1919479&lt;/ulink&gt;]. In February 2018, the company expected to initiate patient enrollment in mid-2018 [&lt;ulink linkID="2007699" linkType="Reference"&gt;2007699&lt;/ulink&gt;].  In June 2018, a randomized,  parallel assignment, quadruple (participant, care provider, investigator, outcomes assessor), interventional, double-blind, multi-center phase III trial (&lt;ulink linkID="297036" linkType="Protocol"&gt;NCT03138733&lt;/ulink&gt;; BPR-CS-009) was initiated in collaboration with Department of Health and Human Services in the US,  Bulgaria, Georgia, Germany, Hungary, Russian Federation, Spain,  Ukraine and Israel in patients (expected n = 390) with complicated Staphylococcus aureus bacteremia  including infective endocarditis  to compare the efficacy and safety of ceftobiprole medocaril compared with daptomycin. The primary endpoint was  overall success at the post-treatment evaluation (PTE) visit. At that time, the trial was expected to complete in August 2021. In April 2019, the trial was ongoing [&lt;ulink linkID="2145763" linkType="Reference"&gt;2145763&lt;/ulink&gt;].  &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Miscellaneous studies&lt;/subtitle&gt;In April 2016, results from a multicenter, open label, single dose, phase I study that examined the pharmacokinetics of ceftobiprole medocaril among pediatric patients who need systemic antibiotics (n = 62) were presented at the 26th ECCMID in Amsterdam, the Netherlands. Patients aged 3 months to &amp;lt; 18 years were treated with ceftobiprole as a 2-h infusion: &amp;lt; 2 year to &amp;gt;/= 3 months (15 mg/kg), &amp;lt; 6 and &amp;gt;/= 2 years (15 mg/kg), &amp;gt;/= 6 and &amp;lt; 12 years (10 mg/kg) and &amp;gt;/= 12 and &amp;lt; 18 years (7 mg/kg), with dose not exceeding &amp;gt; 500 mg in any patient. Mean Cmax and AUCinfinity values observed in pediatric patients aged 3 months to &amp;lt; 12 years were comparable with that of adults, while Cmax values were approximately 40% lower and approximately 20% lower in subjects aged 12 to &amp;lt; 18 years compared with adults [&lt;ulink linkID="1750951" linkType="Reference"&gt;1750951&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2016, data from a multicenter, open-label, single dose study in 22 subjects were presented at the 26th ECCMID in Amsterdam, the Netherlands. After 2 h single infusion, the AUC (0 to t), Cmax and Tmax obtained were 61.3, 3.89 and 13.6 micro.h/ml, 11.9, 0.620 and 2.20 microg/ml and 2.50, 4 and 4 h in unbound plasma, cancellous and cortical bones, respectively. Ceftobiprole was generally well-tolerated with an acceptable safety profile [&lt;ulink linkID="1750976" linkType="Reference"&gt;1750976&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2016, data from an open-label, single-center, parallel group study in 25 severely-obese and non-obese subjects were presented at the 26th ECCMID in Amsterdam, the Netherlands. In severely obese and non-obese subjects, the Cmax, AUC (0 to tz), half-life, volume of distribution, clearance and target MIC of 4 mg/l obtained in plasma were 21.4 microg/l, 91 microg. h/l, 3.4 h, 27.2 l, 5.6 l/h and 76.6 mg/l; 30.2 microg/l, 110 microg.h/ml, 3.2 h, 21.6 l, 4.7 l/h and 79.7 mg/l, respectively. There were no reports of deaths, serious adverse events or significant adverse events and adverse events which lead to discontinuation of treatment [&lt;ulink linkID="1751027" linkType="Reference"&gt;1751027&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2015, Basilea planned to discuss the design of a phase III program for two cross-supportive phase III studies in CABP and ABSSSI with the FDA; at that time, the company  stated that  it might initiate a phase III study in bacteremia (blood stream infections) caused by S aureus [&lt;ulink linkID="1704441" linkType="Reference"&gt;1704441&lt;/ulink&gt;]. In December 2015, Basilea was preparing phase III protocols for cross-supportive studies for ABSSSI, CABP and bacteremia, including endocarditis, for submission to the FDA in 1Q16, seeking SPAs [&lt;ulink linkID="1723896" linkType="Reference"&gt;1723896&lt;/ulink&gt;]. In April 2016, protocol preparation was ongoing for three NDA-supporting phase III trials in S aureus bacteremia, ABSSSI and CABP. At that time, the  phase III program was expected to start by the end of that year or the beginning of 2017, initially in bacteremia and ABSSSI  [&lt;ulink linkID="1753308" linkType="Reference"&gt;1753308&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2010, data were presented at the European Congress of Clinical Microbiology and Infectious Disease in Vienna, Austria, showing that the drug had no significant effect on intestinal flora in healthy subjects [&lt;ulink linkID="1090082" linkType="Reference"&gt;1090082&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Results from a double-blind, multiple-dose study were reported in September 2006 at the 46th ICAAC meeting in San Francisco, CA. A total of 12 volunteers were given a single 1000 mg infusion of the ceftobiprole on days 1 and 8 and three infusions on days 2 to 7. No difference in the pharmacokinetics of the drug was seen from day 1 to 8 and the regimen was well tolerated. Most adverse events were mild-to-moderate and the most common events were dysgeusia, abdominal pain, headache and nausea. Severe adverse events were reported in three patients, including pain, dysgeusia, abdominal pain, headache and nausea; however, all adverse events were resolved. No abnormalities in vital signs, physical examination or laboratory parameters were found [&lt;ulink linkID="691456" linkType="Reference"&gt;691456&lt;/ulink&gt;]. Further pharmacokinetic data were reported at the 17th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in Munich, Germany, in April 2007. Ceftobiprole did not cause QT prolongation at 500 and 100 mg doses [&lt;ulink linkID="780371" linkType="Reference"&gt;780371&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2003, clinical data were presented at the 43rd ICAAC meeting in Chicago, IL. The pharmacokinetic profile of  ceftobiprole administered as a single 250 mg iv dose was compared in 5 healthy volunteers and 15 volunteers with mild, moderate or severe renal impairment. Cmax and steady state volume of distribution values were similar for all groups [&lt;ulink linkID="503042" linkType="Reference"&gt;503042&lt;/ulink&gt;], [&lt;ulink linkID="507890" linkType="Reference"&gt;507890&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By October 2001, ceftobiprole medocaril was in phase I testing in Europe [&lt;ulink linkID="426387" linkType="Reference"&gt;426387&lt;/ulink&gt;], [&lt;ulink linkID="436929" linkType="Reference"&gt;436929&lt;/ulink&gt;], [&lt;ulink linkID="463827" linkType="Reference"&gt;463827&lt;/ulink&gt;]. In September 2002, phase I clinical data on ceftobiprole were presented at the 42nd ICAAC meeting in San Diego, CA. The trial had a randomized, double-blind, single ascending-dose study design and a dose level of 750 mg bid was predicted as being adequate for the treatment of MRSA infection [&lt;ulink linkID="465436" linkType="Reference"&gt;465436&lt;/ulink&gt;], [&lt;ulink linkID="463945" linkType="Reference"&gt;463945&lt;/ulink&gt;]. Clinical simulations on ceftobiprole were also presented at the same meeting. Monte Carlo predictions using phase I data were used to assess dosing regimens; &lt;br&gt;&lt;/br&gt; tid and 750 mg bid were shown to have the highest probability of curing MRSA infections [&lt;ulink linkID="463942" linkType="Reference"&gt;463942&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In June 2018, in vitro data were presented at the 2018ASM Microbe Conference in Atlanta, GA. Ceftobiprole exhibited MIC50/90 value of 0.5/2 mg/l against S aureus (99.4% susceptible). Ceftobiprole exhibited MIC50/90 values of 1/2 and 0.5/0.5 mg/l against MRSA and MSSA, respectively. Against 25 CoNS isolates, ceftobiprole exhibited MIC50/90 value of 1/4 mg/l, and all MIC values were &amp;lt;/= 4 mg/l. Ceftobiprole exhibited potent activity against E faecalis with MIC50/90 value of 0.5/2 mg/l [&lt;ulink linkID="2043122" linkType="Reference"&gt;2043122&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2017, in vivo data were presented at the 27th ECCMID in Vienna, Austria. The antibiotics ceftobiprole, clindamycin and linezolid demonstrated highest pulmonary efficacy in community-acquired-MRSA model; also exhibited a significant reduction in the splenic bacterial load; and ceftobiprole and clindamycin treated groups exhibited highest proportion of negative spleen. In the lungs and spleen of both early-death and surviving animals of hospital-acquired-MRSA model, all antibiotic treatment groups exhibited significant antibacterial effect; and the agents clindamycin and ceftobiprole demonstrated most activity [&lt;ulink linkID="1920479" linkType="Reference"&gt;1920479&lt;/ulink&gt;]. Further in vitro data were presented at the same conference. At clinically achievable levels, ceftobiprole produced kill kinetics typical for beta-lactams against S aureus, which resulted killing effects against both MSSA and MRSA. Ceftobiprole also exhibited a more potent early bactericidal effect relative to vancomycin against hVISA strain and the VISA strain [&lt;ulink linkID="1920328" linkType="Reference"&gt;1920328&lt;/ulink&gt;]. At the same conference, further in vitro data were presented. For an isolate #88236, treatment with ceftobiprole (2 mg/l) showed prolonged lag phase (approximately 7 h longer) and overtly weakened the growth rate when compared with 0 and 1 mg/l colonies [&lt;ulink linkID="1920438" linkType="Reference"&gt;1920438&lt;/ulink&gt;]. Further in vitro data were presented at the same conference.  Against 526 isolates of coagulase-negative staphylococci, ceftobiprole had MIC50/90 value of 0.5/2 mg/ml  (99.2% of susceptible) and all MIC values were &amp;lt;/ = 8 mg/ml. Ceftobiprole showed potent activity against Enterococcus faecalis (MIC 50/90 0.5/2 mg/ml), while did not observed against Enterococcus faecium (MIC 50/90 &amp;gt; 4/&amp;gt;4 mg/ml) [&lt;ulink linkID="1920392" linkType="Reference"&gt;1920392&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2015, preclinical data were presented at the 2015 ICAAC/ICC Meeting in San Diego, CA. Ceftobiprole demonstrated potent antibacterial activity against methicillin-susceptible (MS) Staphylococcus aureus (n = 1529; MIC50 = 0.25 microg/ml, MIC90 = 0.5 microg/ml; MIC range = 0.03 to 2 microg/ml; 100% susceptibility), MS-coagulase-negative staphylococci (CoNS; n = 78; MIC50 = 0.25 microg/ml, MIC90 = 0.5 microg/ml; MIC range = 0.015 to 1 microg/ml), beta-haemolytic streptococci (n = 253; MIC50 = 0.015 microg/ml, MIC90 = 0.03 microg/ml; MIC range = &amp;lt;/= 0.008 to 0.03 microg/ml) and Streptococcus pneumoniae (n = 804; MIC50 = &amp;lt;/= 0.008 microg/ml, MIC90 = 0.5 microg/ml; MIC range = &amp;lt;/= 0.008 to 4 microg/ml; 99.0% susceptibility) [&lt;ulink linkID="1693371" linkType="Reference"&gt;1693371&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2015, preclinical data from BSAC Surveillance Project were presented at the 25th ECCMID in Copenhagen, Denmark. Ceftobiprole demonstrated strong in vitro antimicrobial activity against all S aureus isolates attributable to hospital-acquired respiratory tract infections in the UK and Ireland from 2011 to 2013, and 100% of all MRSA isolates had completely susceptible to ceftobiprole [&lt;ulink linkID="1653510" linkType="Reference"&gt;1653510&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2013, results from in vitro testing from several European surveillance studies conducted from 2008 to 2010 were presented at the 23rd European Congress of Clinical Microbiology and Infectious Diseases in Berlin, Germany; ceftobiprole was highly potent against MRSA, including strains with decreased susceptibility to &lt;ulink linkID="2911" linkType="Drug"&gt;daptomycin&lt;/ulink&gt;, &lt;ulink linkID="11036" linkType="Drug"&gt;linezolid&lt;/ulink&gt; and &lt;ulink linkID="44401" linkType="Drug"&gt;vancomycin&lt;/ulink&gt;, and was also highly potent against a large collection of European Gram-positive clinical isolates comprising staphylococci, streptococci and enterococci, including strains resistant to commonly used antibiotics. Further data demonstrated that ceftobiprole had potent activity similar to &lt;ulink linkID="44317" linkType="Drug"&gt;ceftazidime&lt;/ulink&gt; and &lt;ulink linkID="2736" linkType="Drug"&gt;cefepime&lt;/ulink&gt; against clinically relevant Gram-negative pathogens, specifically Enterobacteriaceae and Pseudomonas aeruginosa [&lt;ulink linkID="1411602" linkType="Reference"&gt;1411602&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2010, preclinical data were presented at the 50th ICAAC meeting in Boston, MA. The efficacy of ceftobiprole alone and in combination with vancomycin was tested in a rat MRSA infective endocarditis model. Ceftobiprole (100 mg/kg) was demonstrated to reduce bacteria resulting in sterile cardiac vegetation in 47% of rats compared with vancomycin monotherapy. Ceftobiprole (60 mg/kg twice a day) in combination with vancomycin (120 mg/kg) reduced bacteria by 4.6 log10 CFU/g [&lt;ulink linkID="1126099" linkType="Reference"&gt;1126099&lt;/ulink&gt;]. The drug also demonstrated efficacy in a rat model of vancomycin-intermediate S aureus endocarditis, both as a monotherapy and in combination with vancomycin [&lt;ulink linkID="1126101" linkType="Reference"&gt;1126101&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2006, preclinical data were presented at the 46th ICAAC meeting in San Francisco, CA. Ceftobiprole and comparators were tested against 37 MRSA and 51 strains of methicillin-resistant coagulase-negative staphylococci (MRCNS), recovered from patients with endocarditis. The MIC90 values against MRSA for ceftobiprole (0.125 to 2 microg/ml), &lt;ulink linkID="2911" linkType="Drug"&gt;daptomycin&lt;/ulink&gt; (0.125 to 1), &lt;ulink linkID="11036" linkType="Drug"&gt;linezolid&lt;/ulink&gt; (0.025 to 4) and &lt;ulink linkID="44401" linkType="Drug"&gt;vancomycin&lt;/ulink&gt; (0.5 to 2) were obtained. The MIC90s ranges against MRCNS were 0.125 to 4, 0.125 to 1, 0.25 to 2 and 0.25 to 2 microg/ml, respectively [&lt;ulink linkID="689684" linkType="Reference"&gt;689684&lt;/ulink&gt;]. In a further study, the same panel of compounds was tested against 31 MRSA and 65 MCNS isolates, recovered from patients with bone and joint infections. Similar results were achieved, with the inhibitory activity of ceftobiprole equivalent to that of daptomycin, linezolid and vancomycin [&lt;ulink linkID="689687" linkType="Reference"&gt;689687&lt;/ulink&gt;]. In a study evaluating the drug against 463 anaerobic bacterial strains, ceftobiprole was compared to &lt;ulink linkID="29446" linkType="Drug"&gt;piperacillin&lt;/ulink&gt;, &lt;ulink linkID="44406" linkType="Drug"&gt;imipenem&lt;/ulink&gt;, &lt;ulink linkID="3616" linkType="Drug"&gt;meropenem&lt;/ulink&gt;, &lt;ulink linkID="12543" linkType="Drug"&gt;ertapenem&lt;/ulink&gt;, &lt;ulink linkID="12978" linkType="Drug"&gt;moxifloxacin&lt;/ulink&gt;, &lt;ulink linkID="51794" linkType="Drug"&gt;chloramphenicol&lt;/ulink&gt;, &lt;ulink linkID="55388" linkType="Drug"&gt;metronidazole&lt;/ulink&gt; and &lt;ulink linkID="44370" linkType="Drug"&gt;clindamycin&lt;/ulink&gt;. The results showed ceftobiprole to be active (MICs &amp;lt; 0.016 to 4 microg/ml), against all Gram-positive strains, excluding Clostridium difficile and Peptostreptococcus anaerobius. The compound was less effective against beta-lactam positive strains, most notably beta-lactam positive Bacillus species (MICs approximately 16 to 64 microg/ml) [&lt;ulink linkID="689697" linkType="Reference"&gt;689697&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In December 2005, data were presented at the 45th ICAAC meeting in Washington, DC. MIC values for ceftobiprole against a panel of Gram-negative bacteria ranged from 0.015 microg/ml for Providencia stuartii to 4 microg/ml for P aeruginosa. Ceftobiprole resistant mutants occurred with similar frequency to those of other beta-lactams [&lt;ulink linkID="640296" linkType="Reference"&gt;640296&lt;/ulink&gt;]. In vitro MIC values of 2 microg/ml or less were obtained for ceftobiprole against 98.6% of isolates of Haemophilus influenzae and Moraxella catarrhalis tested [&lt;ulink linkID="640314" linkType="Reference"&gt;640314&lt;/ulink&gt;]. The drug also demonstrated the lowest incidence of spontaneous mutations yielding resistant strains of these species [&lt;ulink linkID="640386" linkType="Reference"&gt;640386&lt;/ulink&gt;]. Kill kinetics of ceftobiprole medocaril against these species were similar to those of other beta-lactams, with twice the MIC being bactericidal against all strains after 24 h [&lt;ulink linkID="640316" linkType="Reference"&gt;640316&lt;/ulink&gt;]. Low MICs and good killing kinetics were also observed against strains of Staphylococci [&lt;ulink linkID="640317" linkType="Reference"&gt;640317&lt;/ulink&gt;], [&lt;ulink linkID="640383" linkType="Reference"&gt;640383&lt;/ulink&gt;]. The drug was found to be a weak inducer of AmpC beta-lactamases in Enterobacter cloacae [&lt;ulink linkID="640320" linkType="Reference"&gt;640320&lt;/ulink&gt;]. In a comparative in vitro study of 6 agents, ceftobiprole was most active against Streptococcus pneumoniae with MIC values in the range of 0.008 to 1 microg/ml [&lt;ulink linkID="640321" linkType="Reference"&gt;640321&lt;/ulink&gt;]. Ceftobiprole (1 microg/ml) inhibited 79% of Acinetobacter baumannii but was not effective against Stenotrophomonas maltophilia [&lt;ulink linkID="640380" linkType="Reference"&gt;640380&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2004, preclinical data were presented at the 44th ICAAC meeting in Washington, DC. In a rat tissue cage model of chronic MRSA infection, using a strain isolated from a case of catheter-related sepsis, animals were administered vancomycin 50 mg/kg bid or low-dose (equivalent to 50 mg/kg) or high-dose (equivalent to 150 mg/kg) ceftobiprole bid ip for 7 days, starting 2 weeks post-infection. The high dose provided ceftobiprole levels over 4 microg/ml for over 75% of each dosing interval in the tissue cage fluid and there was no significant accumulation. This dose induced equivalent killing to vancomycin 50 mg/kg and no resistance was detected [&lt;ulink linkID="568209" linkType="Reference"&gt;568209&lt;/ulink&gt;]. The activity of 71 mg/kg sc qid ceftobiprole (equivalent to 50 mg/kg) was compared to 50 mg/kg ip qid &lt;ulink linkID="2736" linkType="Drug"&gt;cefepime&lt;/ulink&gt; and 50 mg/kg im bid &lt;ulink linkID="44384" linkType="Drug"&gt;ceftriaxone&lt;/ulink&gt; in mouse models of Haemophilus influenzae, Enterobacter cloacae or Klebsiella pneumoniae pneumonias, in which treatment started 24 h post-infection. None of the drugs were active against extended-spectrum beta-lactamase (ESBL)-expressing K pneumoniae and no significant differences in efficacy of the three drugs in the pneumonia models were detected. In vitro, ceftobiprole treatment was the most effective against H influenzae and E cloacae, exhibiting MIC values of less than 0.125 microg/ml against both organisms. Against ESBL-negative K pneumoniae, ceftobiprole displayed an MIC value of 0.5 microg/ml, compared to less than 0.125 microg/ml for cefepime [&lt;ulink linkID="568482" linkType="Reference"&gt;568482&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Also in October-November 2004 at the 44th ICAAC meeting in Washington DC, additional data were presented. The drug was active against all staphylococcal strains tested (MIC = 0.12-2 microg/ml), irrespective of resistance to other antibacterial agents, and proved refractory to the development of endogenous resistance. The maximum MIC achieved after 50 passages (in 1 out 10 strains) was 8 microg/ml [&lt;ulink linkID="568659" linkType="Reference"&gt;568659&lt;/ulink&gt;], [&lt;ulink linkID="568651" linkType="Reference"&gt;568651&lt;/ulink&gt;]. When tested against pneumococci strains, serial passage yielded a MIC range of 0.03 to 1 microg/ml for up to 50 dilutions in the presence of subinhibitory concentrations of antibiotics. Furthermore, single-step experiments of ceftobiprole in the presence of 1 to 8x MIC showed low frequencies of resistance emergence [&lt;ulink linkID="568654" linkType="Reference"&gt;568654&lt;/ulink&gt;]. Ceftobiprole Etest (quantitative gradient diffusion assay system) MIC values were comparable to microdilution MIC values, although the values for staphylococci were consistently slightly higher than those observed for microdilution MIC values [&lt;ulink linkID="569108" linkType="Reference"&gt;569108&lt;/ulink&gt;]. In time-kill studies, ceftobiprole, at 2 x MIC, achieved 99% bactericidal activity by 24 h in 11/12 pneumococcal strains tested [&lt;ulink linkID="568656" linkType="Reference"&gt;568656&lt;/ulink&gt;]. In in vitro studies evaluating the activity of the drug against strains of P aeruginosa susceptible or resistant to ceftazidime, MIC50/90 values against ceftazidime-susceptible and -resistant isolates were 8/16 and 16/64 mg/l, respectively; corresponding values for ceftazidime were 4/8 and 64/&amp;gt;64 mg/l, respectively. Of the 28 ceftazidime-susceptible isolates, 11 (39%) and 24 (85.7%) were inhibited by ceftobiprole at 4 and 8 mg/l, respectively. Similarly, against 29 ceftazidime-resistant strains, 3 (10.3%) and 12 (41.4%) were inhibited by ceftobiprole at 4 and 8 mg/l, respectively [&lt;ulink linkID="568650" linkType="Reference"&gt;568650&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2004, preclinical data were presented at the sixth SMi Superdrugs &amp;amp; Superbugs: A Focus on Antibacterials meeting in London, UK. Ceftobiprole demonstrated MIC50 and MIC90 values of 2 and 4 microg/ml against MRSA. It also showed activity against Enterobacter cloacae and Pseudomonas aeruginosa [&lt;ulink linkID="526547" linkType="Reference"&gt;526547&lt;/ulink&gt;]. Further data presented at the Antibacterial Drug Discovery &amp;amp; Development Summit in March 2004 in Cherry Hill, USA indicated that in vitro selection of drug-resistant mutants of ceftobiprole led to relatively small increases in MIC, and the resistance mutants appeared phenotypically unstable [&lt;ulink linkID="536696" linkType="Reference"&gt;536696&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2003, preclinical data were presented at the 43rd ICAAC meeting in Chicago, IL. Ceftobiprole exhibited similar activity to ceftriaxone and cefepime against clinical isolates of Enterobacter cloacae, Haemophilus influenzae, Klebsiella pneumoniae and Pseudomonas aeruginosa [&lt;ulink linkID="503458" linkType="Reference"&gt;503458&lt;/ulink&gt;], [&lt;ulink linkID="503459" linkType="Reference"&gt;503459&lt;/ulink&gt;]. In a mouse model of H influenzae pneumonia, administration of ceftobiprole (71 mg/kg sc qid for 2 days, starting 24 h post-infection) sterilized 9 of 15 lungs; however, treatment with cefepime (50 mg/kg ip qid) and ceftriaxone (50 mg/kg im bid) sterilized all lungs [&lt;ulink linkID="503457" linkType="Reference"&gt;503457&lt;/ulink&gt;]. Ceftobiprole demonstrated in vivo activity against MRSA (MIC = 2 microg/ml) and vancomycin-intermediate S aureus (MIC = 0.5 microg/ml) in a rabbit model of aortic valve endocarditis. It also reduced viable MRSA levels from 6.84 +/- 0.39 log(10) colony-forming units (cfu)/g in the control to 1.69 +/- 2.36 log(10) cfu/g [&lt;ulink linkID="503946" linkType="Reference"&gt;503946&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2002, preclinical data were presented at the 42nd ICAAC meeting in San Diego, CA. In a murine model of S pneumoniae-induced pneumonia, MIC/MBC values for ceftobiprole towards beta-lactam-resistant pneumococci were 0.25/0.5 microg/ml to 1.0/2.0 microg/ml. Ceftobiprole (2 to 17 mg/kg) provided 100% protection against both beta-lactam-sensitive-and -resistant S pneumoniae [&lt;ulink linkID="463938" linkType="Reference"&gt;463938&lt;/ulink&gt;], [&lt;ulink linkID="465436" linkType="Reference"&gt;465436&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Ceftobiprole has a broad spectrum of activity against Gram-positive pathogens (including penicillin resistant pneumococci and Enterococcus faecalis) as well as potent activity against Gram-negative pathogens. It inhibits most transpeptidases, including the penicillin-binding protein PBP2'. It is bactericidal and did not show resistance development in vitro and in animal models [&lt;ulink linkID="436889" linkType="Reference"&gt;436889&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Ceftobiprole inhibits the penicillin-binding protein, PBP2', rapidly through a unique mode of interaction. A high rate of acylation, high affinity and a low rate of deacylation prevents factors which would normally make this protein resistant to beta-lactams. Ceftobiprole has demonstrated promising in vitro and in vivo activity against a range of gram-positive bacteria [&lt;ulink linkID="299916" linkType="Reference"&gt;299916&lt;/ulink&gt;], [&lt;ulink linkID="421311" linkType="Reference"&gt;421311&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;In February 2009, Basilea filed claims in arbitration against J&amp;amp;J and its affiliates in relation to the delays in US and EU approval [&lt;ulink linkID="986214" linkType="Reference"&gt;986214&lt;/ulink&gt;]. In January 2010, Basilea anticipated a tribunal decision by the end of 2010 [&lt;ulink linkID="1075015" linkType="Reference"&gt;1075015&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2008, the EMA's Pediatric Committee adopted a positive opinion on a pediatric investigation plan (PIP) for the product for infectious diseases [&lt;ulink linkID="971771" linkType="Reference"&gt;971771&lt;/ulink&gt;]. In August 2012,  the EMEA's Pediatric Committee (PDCO) adopted a positive opinion on a modification to the agreed PIP [&lt;ulink linkID="1317791" linkType="Reference"&gt;1317791&lt;/ulink&gt;]. In September 2012, the EMA's PDCO adopted a positive opinion on a PIP [&lt;ulink linkID="1323706" linkType="Reference"&gt;1323706&lt;/ulink&gt;]. In March 2013, the Pediatric Committee adopted a positive opinion to modifications of the agreed PIP [&lt;ulink linkID="1397196" linkType="Reference"&gt;1397196&lt;/ulink&gt;]. In February 2014, the PDCO adopted a positive opinion on modification to the agreed PIP  for pneumonia [&lt;ulink linkID="1528112" linkType="Reference"&gt;1528112&lt;/ulink&gt;].  In October 2016,   the EMA's Pediatric Committee adopted a positive opinion on further modification to an agreed  PIP for the treatment of  pneumonia  [&lt;ulink linkID="1870943" linkType="Reference"&gt;1870943&lt;/ulink&gt;]. In November 2018,   the EMA's Pediatric Committee adopted a positive opinion on further modification to an agreed  PIP for the treatment of  pneumonia [&lt;ulink linkID="2102162" linkType="Reference"&gt;2102162&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Ceftobiprole has broad-spectrum activity against many pathogens that cause pneumonia. Its spectrum extends to isolates resistant to other commonly used antibiotics like penicillin-resistant Streptococcus pneumoniae (PRSP), methicillin-resistant Staphylococcus aureus (MRSA) or Staphylococcus aureus [&lt;ulink linkID="1504454" linkType="Reference"&gt;1504454&lt;/ulink&gt;].&lt;br&gt;&lt;/br&gt;&lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><ExpertReview>&lt;para&gt;There are two evaluations of this therapy. The first examines the development of the soluble prodrug BAL-5788, and the second provides an overview of the development of BAL-9141 (Ro-63-9141).&lt;br/&gt;&lt;/para&gt;&lt;para&gt;Ian Chopra, Antimicrobial Research Centre and Division of Microbiology, &lt;ulink linkType="Company" linkID="22199"&gt;University of Leeds&lt;/ulink&gt;, Leeds, UK &lt;/para&gt;&lt;para&gt;Submission date: 6 May 2003&lt;br/&gt;Publication date: 14 November 2003&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Introduction&lt;/subtitle&gt;Resistance to antibiotics is becoming an increasingly difficult problem in the management of bacterial infections. The greatest problems are currently posed by Gram-positive pathogens such as methicillin-resistant Staphylococcus aureus (MRSA), &lt;ulink linkType="Drug" linkID="44401"&gt;vancomycin&lt;/ulink&gt;-resistant enterococci (VRE) and penicillin-resistant pneumococci (PRP) [&lt;ulink linkType="reference" linkID="493656"&gt;493656&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="493658"&gt;493658&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="483170"&gt;483170&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="512635"&gt;512635&lt;/ulink&gt;]. Recently, there has been considerable interest in developing new cephalosporins that may be used to control such infections [&lt;ulink linkType="reference" linkID="483170"&gt;483170&lt;/ulink&gt;]. One of these agents is &lt;ulink linkType="Drug" linkID="36492"&gt;BAL-5788&lt;/ulink&gt; (formerly Ro-65-5788), which is being developed by BASILEA Pharmaceutica. Currently in phase II clinical trials [&lt;ulink linkType="reference" linkID="436889"&gt;436889&lt;/ulink&gt;], &lt;ulink linkType="Drug" linkID="36492"&gt;BAL-5788&lt;/ulink&gt; is a carbamate prodrug, which is rapidly cleaved in the blood [&lt;ulink linkType="reference" linkID="483170"&gt;483170&lt;/ulink&gt;] to yield the active compound BAL-9141 (&lt;ulink linkType="Drug" linkID="36492"&gt;Ro-63-9141&lt;/ulink&gt;; a compound formerly under development by Roche). Development of the prodrug has been necessary because BAL-9141 itself is not sufficiently water soluble for direct administration to humans [&lt;ulink linkType="reference" linkID="298364"&gt;298364&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="483170"&gt;483170&lt;/ulink&gt;]. This evaluation considers the properties of &lt;ulink linkType="Drug" linkID="36492"&gt;BAL-5788&lt;/ulink&gt;/9141 and the potential for introduction of &lt;ulink linkType="Drug" linkID="36492"&gt;BAL-5788&lt;/ulink&gt; as a new antibiotic.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Synthesis and SAR&lt;/subtitle&gt;A process for the synthesis of &lt;ulink linkType="Drug" linkID="36492"&gt;BAL-5788&lt;/ulink&gt; was originally described in WO-09965920. Since then an improved synthesis has been reported [WO-00190111]. In this patent, the route to &lt;ulink linkType="Drug" linkID="36492"&gt;BAL-5788&lt;/ulink&gt; consisted of acylation of a cephem intermediate 7-aminocephalosporanic acid with (Z)-5-(amino-[1,2,4]-thiadiazol-3-yl)-trityloxyimino-thioacetic acid S-benzothiazol-2-yl ester. The carboxylic acid group on the cephem was then protected, and the intermediate oxidized using either an inorganic hypohalide (such as sodium hypochlorite) in the presence of 2,2,6,6-tetramethyl-1-piperidinyloxy radical (TEMPO), or manganese dioxide, to yield the corresponding aldehyde intermediate. The aldehyde was reacted with an ylide phosphonium salt to give a protected pyrrolidinone-3-ylidenemethyl cephem. The amine group of the cephalosporin intermediate was deprotected using triethylsilane prior to reaction with 5-methyl-2-oxo-[1,3]dioxolol-4-ylmethyl ester 4-nitro phenyl ester to yield a protected vinyl-pyrolidinone cephalosporine derivative. The final step of the synthesis involved acidic cleavage of the hydroxy and carboxylic acid protecting groups [WO-00190111].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Preclinical Development&lt;/subtitle&gt;BAL-9141 exhibits particularly good in vitro activity against Gram-positive pathogens [&lt;ulink linkType="reference" linkID="403338"&gt;403338&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="481511"&gt;481511&lt;/ulink&gt;]. Against staphylococci MIC values were 0.25 to 1 microg/ml for methicillin-sensitive S aureus (&lt;ulink linkType="Company" linkID="1006219"&gt;MSSA&lt;/ulink&gt;), 0.5 to 4 microg/ml for MRSA, 0.12 to 1 microg/ml for methicillin-sensitive Staphylococcus epidermidis (MSSE) and 1 to 4 microg/ml for methicillin-resistant S epidermidis (MRSE); in addition good activity was demonstrated against a range of other less frequently encountered pathogenic staphylococci including S haemolyticus, S hominis, S saprophyticus, S sciuri and S warneri. Against pneumococci MIC values were 0.015 to 0.03 microg/ml for penicillin-sensitive strains and 0.03 to 2 microg/ml for PRP. Activity against most other Gram-positive pathogens such as alpha- and beta-hemolytic streptococci was good, with the exception of VRE. The activity of BAL-9141 against Gram-negative pathogens was more variable, with good activity against pathogenic Neisseria spp, Haemophilus influenzae, and Moraxella catarrhalis, as well as Proteus mirabilis; moderate activity was observed against Pseudomonas aeruginosa and clinical isolates of Enterobacteriaceae, but the compound showed poor activity against Proteus vulgaris and against Klebsiella pneumoniae containing extended-spectrum beta-lactamases (ESBLs) [&lt;ulink linkType="reference" linkID="503458"&gt;503458&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="503459"&gt;503459&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Good activity of BAL-9141 against many clinically significant anerobic bacteria (MIC50 = 1 microg/ml) has also been observed [&lt;ulink linkType="reference" linkID="481510"&gt;481510&lt;/ulink&gt;], although the important anaerobe Bacteroides fragilis was less susceptible (MIC50 = 16 microg/ml), and cefoxitin-resistant strains were also resistant to BAL-9141.&lt;/para&gt;&lt;para&gt;The activity of BAL-9141 against MRSA is one of the most interesting properties of this cephalosporin. MRSA resist other beta-lactams by two mechanisms. One involves the production of penicillinase that hydrolyzes beta-lactam antibiotics, rendering them biologically inactive. The second mechanism involves the acquisition and expression of a new penicillin-binding protein (PBP) by MRSA strains. Methicillin-sensitive strains of S aureus possess three penicillin binding proteins (PBPs 1, 2 and 3) that exhibit transpeptidase activity and participate in the formation of essential cross-links between neighbouring UDP-MurNAc-pentapeptide side chains in nascent peptidoglycan [&lt;ulink linkType="reference" linkID="493656"&gt;493656&lt;/ulink&gt;]. These PBPs are inactivated by exposure to methicillin and other beta-lactam antibiotics leading to inhibition of peptidoglycan cross-linking and eventual cell death. MRSA expresses an additional PBP (so-called PBP2', or PBP2a) encoded by the chromosomal mecA determinant. This PBP has very low affinity for methicillin and other beta-lactam antibiotics compared with the normal PBPs present in &lt;ulink linkType="Company" linkID="1006219"&gt;MSSA&lt;/ulink&gt; [&lt;ulink linkType="reference" linkID="493656"&gt;493656&lt;/ulink&gt;]. Thus, even though PBPs 1 to 3 in MRSA are inactivated by methicillin, PBP2a remains insuceptible to methicillin and most other beta-lactam agents and continues to perform essential cross-linking in the absence of normal PBP activity [&lt;ulink linkType="reference" linkID="493656"&gt;493656&lt;/ulink&gt;]. The in vitro activity of BAL-9141 against MRSA also extends to clinical isolates of &lt;ulink linkType="Drug" linkID="44401"&gt;vancomycin&lt;/ulink&gt;-resistant S aureus (VRSA) [&lt;ulink linkType="reference" linkID="506854"&gt;506854&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="512635"&gt;512635&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;New beta-lactam antibiotics must possess stability against hydrolysis by staphylococcal penicillinase and exhibit high affinity for PBP2a if they are to be considered for use against infections caused by MRSA. BAL-9141 does indeed meet these requirements and its anti-MRSA activity reflects both stability to penicillinase and good PBP2a binding properties [&lt;ulink linkType="reference" linkID="403338"&gt;403338&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="438087"&gt;438087&lt;/ulink&gt;]. Thus the rate of hydrolysis of BAL-9141 by the class A beta-lactamase from S aureus PC1 was 10,000-fold lower than that for penicillin G and the IC50 value for binding of BAL-9141 to PBP2a was &amp;gt; 100-fold lower than that for methicillin. Furthermore, BAL-9141 forms very stable acyl-enzyme complexes with PBP2a, apparently through a unique mode of interaction with this PBP [&lt;ulink linkType="reference" linkID="403338"&gt;403338&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;BAL-9141 has displayed activity in a wide range of animal models of infection [&lt;ulink linkType="reference" linkID="403338"&gt;403338&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="438087"&gt;438087&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="463938"&gt;463938&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="503457"&gt;503457&lt;/ulink&gt;]. These include: (i) a rat endocarditis model with MRSA strains, (ii) murine septicemias caused by various Gram-positive and Gram-negative bacterial pathogens, (iii) experimental subcutaneous abscesses caused by &lt;ulink linkType="Company" linkID="1006219"&gt;MSSA&lt;/ulink&gt;, MRSA and &lt;ulink linkType="Drug" linkID="44401"&gt;vancomycin&lt;/ulink&gt;-intermediate-resistant S aureus (VISA/GISA), (iv) a murine model of pneumonia induced by S pneumoniae, and (v) a murine model of pneumonia induced by Haemophilus influenzae type b.&lt;/para&gt;&lt;para&gt;In a model of acute pneumococcal pneumonia, leukopenic mice were infected intratracheally with a range of S pneumoniae stains, variously resistant to antibiotics [&lt;ulink linkType="reference" linkID="463938"&gt;463938&lt;/ulink&gt;]. Six injections of &lt;ulink linkType="Drug" linkID="36492"&gt;BAL-5788&lt;/ulink&gt; and other antibiotics were given twice-daily to infected mice, from 6 h post-infection. MIC values for BAL-9141 ranged from 0.25 to 1 microg/ml, and were 4- to 8-fold lower than for amoxicillin, &lt;ulink linkType="Drug" linkID="44369"&gt;cefotaxime&lt;/ulink&gt; or cefraiaxone. &lt;ulink linkType="Drug" linkID="36492"&gt;BAL-5788&lt;/ulink&gt; over a dose range of 2 to 17 mg/kg gave 100% protection against beta-lactam-sensitive and -resistant pneumococci, whereas up to 400 mg/kg of the other antibiotics tested afforded only patrial protection against dual penicillin- and &lt;ulink linkType="Drug" linkID="44369"&gt;cefotaxime&lt;/ulink&gt;-resistant strains [&lt;ulink linkType="reference" linkID="463938"&gt;463938&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Metabolism and Pharmacokinetics&lt;/subtitle&gt;BAL-9141 has been administered to mice, rats, rabbits, cynomolgus monkeys and dogs to determine pharmacokinetic properties and to extrapolate these data to humans [&lt;ulink linkType="reference" linkID="298361"&gt;298361&lt;/ulink&gt;]. Pharmacokinetic disposition indicated low protein binding (19 to 45%), with a volume of distribution at steady state (Vdss) of 0.25 to 0.36 l/kg. Approximately 70% of the drug is excreted in urine. Extrapolation of animal data to humans indicated a probable half-life of 2 to 3 h and a potential dosing regimen of 700 mg/subject [&lt;ulink linkType="reference" linkID="298361"&gt;298361&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;The physiochemical and pharmacokinetic properties of a range of different prodrugs of BAL-9141 have been studied and the carbamate prodrug &lt;ulink linkType="Drug" linkID="36492"&gt;BAL-5788&lt;/ulink&gt; fulfilled the criteria of sufficient solubility (&gt; 100 mg/ml, compared with &amp;lt; 0.22 mg/ml for BAL-9141) and demonstrated pharmacokinetic equivalence to BAL-9141 in rodents and dogs [&lt;ulink linkType="reference" linkID="298364"&gt;298364&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Pharmacokinetic parameters were calculated using data from phase I studies in healthy subjects. The Cmax and AUC values for BAL-9141 were shown to increase in proportion to the dose. The mean Cmax value was 9.87 to 72.2 microg/ml, after infusion of 125 to 1000 mg, and corresponding AUC values were 20.3 to 251 microg.h/ml. Elimination of BAL-9141 was primarily though urinary excretion, with a t1/2 of 2.84 to 3.47 h. The total systemic clearance was 5.73 to 6.63 l/h, and the Vdss was 17.8 to 19.8 l [&lt;ulink linkType="reference" linkID="463945"&gt;463945&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Pharmacokinetic analysis of a phase I study data from 30 healthy subjects determined the probability distributions for t &amp;gt; MIC (time during which the drug concentration exceeds the MIC) for three different dose regimens (500 or 750 mg bid, or 500 mg tid) [&lt;ulink linkType="reference" linkID="463942"&gt;463942&lt;/ulink&gt;]. Correlation of results with MIC distributions of bacterial species, especially staphylococci, was used to predict the cumulative fraction of response. Data were best described by a two-compartment model.&lt;/para&gt;&lt;para&gt;The safety and pharmacokinetic properties of &lt;ulink linkType="Drug" linkID="36492"&gt;BAL-5788&lt;/ulink&gt; in healthy subjects with impaired renal function has been examined [&lt;ulink linkType="reference" linkID="503042"&gt;503042&lt;/ulink&gt;]. Single intravenous infusions of &lt;ulink linkType="Drug" linkID="36492"&gt;BAL-5788&lt;/ulink&gt; were well tolerated and the systemic clearance of &lt;ulink linkType="Drug" linkID="36492"&gt;BAL-5788&lt;/ulink&gt; correlated with CRCL (the rate of creatinine clearance from the serum by the kidney; a measure of kidney function) indicating that antibiotic levels can be maintained by dose adjustment based on CRCL. Predicted doses, adjusted to maintain plasma levels of BAL-9141 above the target MIC value (4 microg/ml) for 6 h, for normal renal function (CRCL&gt; 80 ml/min), moderate impairment (CRCL = 30 to 80 ml/min), and severe impairment (CRCL &amp;lt; 30 ml/min) were, respectively, 750 mg bid, 500 mg bid and 250 mg per day.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Clinical Development &lt;/subtitle&gt;&lt;subtitle&gt;Phase I&lt;/subtitle&gt;A randomized, double-blind, single ascending-dose study of &lt;ulink linkType="Drug" linkID="36492"&gt;BAL-5788&lt;/ulink&gt; in 40 healthy male subjects has been reported [&lt;ulink linkType="reference" linkID="463945"&gt;463945&lt;/ulink&gt;]. &lt;ulink linkType="Drug" linkID="36492"&gt;BAL-5788&lt;/ulink&gt; doses equivalent to 150, 250, 500, 750 and 1000 mg BAL-9141 were administered by 200 ml intravenous injections over 30 min. A dose level of 750 mg bid was predicted as sufficient for treatment of MRSA infections since, following infusion of 750 mg, plasma concentrations of BAL-9141 exceeded the MIC90 (4 microg/ml) for MRSA for approximately 7 h [&lt;ulink linkType="reference" linkID="463945"&gt;463945&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Using data from a separate Phase I dose escalation study in 30 subjects a dosing regimen was predicted for &lt;ulink linkType="Drug" linkID="36492"&gt;BAL-5788&lt;/ulink&gt; phase II clinical studies [&lt;ulink linkType="reference" linkID="463942"&gt;463942&lt;/ulink&gt;]. Using Monte Carlo simulation combined with in vitro MIC data for BAL-9141, doses of 500 mg tid and 750 mg bid were predicted to have the highest probability of curing MRSA infections [&lt;ulink linkType="reference" linkID="463942"&gt;463942&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;&lt;ulink linkType="Drug" linkID="36492"&gt;BAL-5788&lt;/ulink&gt; has entered phase II trials [&lt;ulink linkType="reference" linkID="436889"&gt;436889&lt;/ulink&gt;]; however, at time of publication no data were available. The drug has received Fast Track designation from the US FDA for the treatment of complicated skin and skin structure infections, an indication which includes infections arising in 1 to 10% of patients undergoing surgery [&lt;ulink linkType="reference" linkID="481324"&gt;481324&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Side Effects and Contraindications&lt;/subtitle&gt;The most frequent adverse side effects reported by patients in phase I studies were taste disturbance and headache; however, no trends or clinically significant changes in laboratory parameters were observed [&lt;ulink linkType="reference" linkID="463945"&gt;463945&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Patent Commentary&lt;/subtitle&gt;The original patent describing the preparation of cephem derivatives, EP-00812846, was granted to &lt;ulink linkType="Company" linkID="19449"&gt;Hoffmann-La Roche AG&lt;/ulink&gt; in December 1997. A later world patent WO-09965920 claiming bipyrrolidinyl-3-ylidenemethyl cephems, including the BASILEA leads, was granted to Roche in 1999. An improved route of synthesis (detailed in this evaluation) was described in WO-00190111, granted to &lt;ulink linkType="Company" linkID="28104"&gt;BASILEA Pharmaceutica AG&lt;/ulink&gt; in November 2001.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Current Opinion&lt;/subtitle&gt;BAL-9141 demonstrates excellent activity against many major pathogens displaying various resistances to other antibiotics. It could be particularly valuable in the treatment of MRSA as well as for drug-resistant streptococci, while maintaining a spectrum resembling a 'third-generation' cephalosporin against other clinically important species. In common with other beta-lactam antibiotics BAL-9141 demonstrates potent bactericidal activity [&lt;ulink linkType="reference" linkID="403338"&gt;403338&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;The anti-MRSA activity of &lt;ulink linkType="Drug" linkID="36492"&gt;BAL-5788&lt;/ulink&gt;/BAL-9141 is of particular interest. MRSA is currently a predominant and dangerous nosocomial pathogen. Unfortunately infections caused by this organism are becoming more difficult to treat as further evolution of drug resistance occurs within the pathogen. &lt;ulink linkType="Drug" linkID="44401"&gt;Vancomycin&lt;/ulink&gt; has become the drug of choice for treating MRSA infections. However, treatment failures, adverse side effects and emergence of &lt;ulink linkType="Drug" linkID="44401"&gt;vancomycin&lt;/ulink&gt; resistant MRSA are leading to urgent requirements for alternative anti-MRSA therapies. &lt;ulink linkType="Drug" linkID="11036"&gt;Linezolid&lt;/ulink&gt; is a new agent recently developed for Gram-positive infections, including MRSA, but resistance to this drug is already developing [&lt;ulink linkType="reference" linkID="451654"&gt;451654&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="485725"&gt;485725&lt;/ulink&gt;]. The need for superior anti-MRSA drugs is therefore highly evident. &lt;ulink linkType="Drug" linkID="36492"&gt;BAL-5788&lt;/ulink&gt; has the potential to fulfill the requirements for an effective anti-MRSA agent. A number of other agents are also in development for the same indication [&lt;ulink linkType="reference" linkID="483170"&gt;483170&lt;/ulink&gt;] and the final regulatory approval of these agents, as well as &lt;ulink linkType="Drug" linkID="36492"&gt;BAL-5788&lt;/ulink&gt;, will depend upon acceptable clinical efficacy and safety profiles.&lt;br/&gt;&lt;/para&gt;&lt;para&gt;Johann DD Pitout, Department of Medical Microbiology, UOFS/Universitas Hospital, Bloemfontein, South Africa&lt;/para&gt;&lt;para&gt;Publication date: 7 January 2000&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Introduction&lt;/subtitle&gt;&lt;ulink linkType="Drug" linkID="36492"&gt;Ro-63-9141&lt;/ulink&gt; is a novel broad-spectrum cephalosporin which was under investigation by &lt;ulink linkType="Company" linkID="26178"&gt;Hoffmann-La Roche&lt;/ulink&gt; and &lt;ulink linkType="Company" linkID="25992"&gt;Chuv&lt;/ulink&gt; (Lausanne) for the potential treatment of resistant Gram-positive and Gram-negative organisms. Hoffmann-La Roche announced discontinuation of their research program into cephalosporin antibiotics, although the drug is available for licensing [&lt;ulink linkType="reference" linkID="364336"&gt;364336&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Synthesis and SAR&lt;/subtitle&gt;&lt;ulink linkType="Drug" linkID="36492"&gt;Ro-63-9141&lt;/ulink&gt; is a pyrrolidinone-3-ylidenmethyl cephalosporin with a 3-R-pyrrolidine residue. The synthesis of this agent comprises a trans-selective Wittig reaction of a 3-formylcephem precursor with a suitably substituted phosphonium as the key step. After the introduction of the 7-acyl side chain and the removal of the protecting groups, &lt;ulink linkType="Drug" linkID="36492"&gt;Ro-63-9141&lt;/ulink&gt; is obtained in the zwitterionic form as a crystalline solid [&lt;ulink linkType="reference" linkID="307068"&gt;307068&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Pharmacology&lt;/subtitle&gt;The potent activity of &lt;ulink linkType="Drug" linkID="36492"&gt;Ro-63-9141&lt;/ulink&gt; against methicillin-resistant Staphylococcus aureus (MRSA) is related to the binding to and subsequent inhibition of certain essential penicillin-binding proteins (PBPs), namely PBP1, PBP2, PBP2a and PBP3 [&lt;ulink linkType="reference" linkID="307072"&gt;307072&lt;/ulink&gt;]. &lt;ulink linkType="Drug" linkID="36492"&gt;Ro-63-9141&lt;/ulink&gt; achieves potent inhibition of PBP2a through a high rate of acylation, high affinity and low rate of deacylation. Its antibacterial activity in Gram-negative organisms is related to its affinity for and inhibition of both PBP1b and PBP2 [&lt;ulink linkType="reference" linkID="307072"&gt;307072&lt;/ulink&gt;].&lt;br/&gt; &lt;br/&gt;The in vitro activity of &lt;ulink linkType="Drug" linkID="36492"&gt;Ro-63-9141&lt;/ulink&gt; was determined against various aerobic and anaerobic Gram-positive and Gram-negative organisms [&lt;ulink linkType="reference" linkID="29317"&gt;29317&lt;/ulink&gt;],	 [&lt;ulink linkType="reference" linkID="298324"&gt;298324&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="298327"&gt;298327&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="298329"&gt;298329&lt;/ulink&gt;]. Of the 76 MRSA strains studied, 50% were inhibited at a concentration of 2 microg/ml of &lt;ulink linkType="Drug" linkID="36492"&gt;Ro-63-9141&lt;/ulink&gt;, while 50% of methicillin-sensitive Staphylococcus aureus (&lt;ulink linkType="Company" linkID="1006219"&gt;MSSA&lt;/ulink&gt;) strains were inhibited at 0.5 microg/ml. MIC50 values of 0.5, 1, 0.5 and 8 microg/ml were obtained for penicillin-resistant Streptococcus pneumoniae (n = 20), methicillin- resistant Staphylococcus epidermidis (n = 19), Enterococcus faecalis (n = 10) and Enterococcus faecium, respectively [&lt;ulink linkType="reference" linkID="298329"&gt;298329&lt;/ulink&gt;]. Killing kinetics showed &lt;ulink linkType="Drug" linkID="36492"&gt;Ro-63-9141&lt;/ulink&gt; to be bacteriocidal against MRSA strains at a concentration of 4 microg/ml [&lt;ulink linkType="reference" linkID="298329"&gt;298329&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;The in vitro susceptibility of various Gram-negative organisms to &lt;ulink linkType="Drug" linkID="36492"&gt;Ro-63-9141&lt;/ulink&gt; had been determined in two separate studies [&lt;ulink linkType="reference" linkID="298317"&gt;298317&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="298327"&gt;298327&lt;/ulink&gt;]. These results showed &lt;ulink linkType="Drug" linkID="36492"&gt;Ro-63-9141&lt;/ulink&gt; to have similar or greater activity to &lt;ulink linkType="Drug" linkID="44369"&gt;cefotaxime&lt;/ulink&gt; and/or &lt;ulink linkType="Drug" linkID="2736"&gt;cefepime&lt;/ulink&gt; against several species of enterobacteriaceae, which included strains of Escherichia coli, Klebsiella pneumoniae and Enterobacter cloacae [&lt;ulink linkType="reference" linkID="298327"&gt;298327&lt;/ulink&gt;]. This agent also showed equal or greater activity to &lt;ulink linkType="Drug" linkID="2736"&gt;cefepime&lt;/ulink&gt; and/or &lt;ulink linkType="Drug" linkID="44317"&gt;ceftazidime&lt;/ulink&gt; against various non-fermenters, including Pseudomonas aeruginosa and Acinetobacter baumanii [&lt;ulink linkType="reference" linkID="298317"&gt;298317&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="298327"&gt;298327&lt;/ulink&gt;]. Furthermore, &lt;ulink linkType="Drug" linkID="36492"&gt;Ro-63-9141&lt;/ulink&gt; showed similar or greater activity to cefoxitin against various clinically significant anaerobes (with the exception of Bacteroides fragilis, where cefoxitin was more potent) [&lt;ulink linkType="reference" linkID="298324"&gt;298324&lt;/ulink&gt;]. In the above mentioned studies, &lt;ulink linkType="Drug" linkID="36492"&gt;Ro-63-9141&lt;/ulink&gt; was also compared to other classes of antimicrobial agents, such as imipenem, &lt;ulink linkType="Drug" linkID="3616"&gt;meropenem&lt;/ulink&gt; and &lt;ulink linkType="Drug" linkID="44438"&gt;ciprofloxacin&lt;/ulink&gt;. These agents proved to be 1 to 3-times more potent than &lt;ulink linkType="Drug" linkID="36492"&gt;Ro-63-9141&lt;/ulink&gt; against the majority of Gram-negative organisms tested [&lt;ulink linkType="reference" linkID="298317"&gt;298317&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="298327"&gt;298327&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;The in vivo activity of &lt;ulink linkType="Drug" linkID="36492"&gt;Ro-63-9141&lt;/ulink&gt; against MRSA COL+ (beta-lactamase-producing strain) was compared to amoxicillin/clavulanic acid (ca) and &lt;ulink linkType="Drug" linkID="44401"&gt;vancomycin&lt;/ulink&gt; (van) in an experimental rat endocarditis model [&lt;ulink linkType="reference" linkID="29816"&gt;29816&lt;/ulink&gt;]. &lt;ulink linkType="Drug" linkID="36492"&gt;Ro-63-9141&lt;/ulink&gt;, in three different doses, was administered as a continuous infusion to achieve a steady state concentration, whilst ca and van were infused at changing flow rates to simulate human kinetics. &lt;ulink linkType="Drug" linkID="36492"&gt;Ro-63-9141&lt;/ulink&gt; successfully treated experimental endocarditis at the three targeted steady state concentrations and was equally or more effective than the comparative treatment with either ca or van [&lt;ulink linkType="reference" linkID="29816"&gt;29816&lt;/ulink&gt;]. Additional in vivo studies showed &lt;ulink linkType="Drug" linkID="36492"&gt;Ro-63-9141&lt;/ulink&gt; to be effective in murine septicemia caused by various Gram- positive and Gram-negative organisms [&lt;ulink linkType="reference" linkID="298317"&gt;298317&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="298329"&gt;298329&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Metabolism&lt;/subtitle&gt;&lt;ulink linkType="Drug" linkID="36492"&gt;Ro-63-9141&lt;/ulink&gt; was administered to mice, rates, rabbits, cynomolgus monkeys and dogs to characterize its pharmocokinectics and to extrapolate animal kinetics to man [&lt;ulink linkType="reference" linkID="298361"&gt;298361&lt;/ulink&gt;]. The disposition of pharmacokinetics of &lt;ulink linkType="Drug" linkID="36492"&gt;Ro-63-9141&lt;/ulink&gt; showed low protein binding (19 to 45%), with a volume of distribution at steady state (Vdss) = 0.25 to 0.36 l/kg) and approximately 70% of the drug excreted in urine. Time normalization for the respective animal species to human time, showed the terminal half-life of &lt;ulink linkType="Drug" linkID="36492"&gt;Ro-63-9141&lt;/ulink&gt; to be approximately 2 to 3 h and the potential dosing regime to be  700 mg/subject bid [&lt;ulink linkType="reference" linkID="298361"&gt;298361&lt;/ulink&gt;]. The physiochemical and pharmacokinetic properties of different prodrugs of &lt;ulink linkType="Drug" linkID="36492"&gt;Ro-63-9141&lt;/ulink&gt; have been studied and the carbamate prodrug Ro-65-5788/001 was found to fulfil the criteria of sufficient solubility (&gt; 100 mg/ml) and the pharmacokinetic equivalence to &lt;ulink linkType="Drug" linkID="36492"&gt;Ro-63-9141&lt;/ulink&gt; in mice, rats and dogs [&lt;ulink linkType="reference" linkID="298364"&gt;298364&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Toxicity&lt;/subtitle&gt;No data currently available.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Current Opinion&lt;/subtitle&gt;Gram-positive organisms, which are resistant to various antimicrobial agents, cause difficult-to-treat community- and hospital-acquired infections. Examples include MRSA, glycopeptide-intermediate S aureus (GISA), &lt;ulink linkType="Drug" linkID="44401"&gt;vancomycin&lt;/ulink&gt;-resistant enterococci (VRE) and penicillin-resistant Streptococcus pneumoniae (PRSpn). These bacteria are often resistant to all of the available cephalosporins. A new generation of cephalosporins with in vivo and in vitro activity against resistant Gram-positive cocci is emerging. Some of these cephalosporins, namely &lt;ulink linkType="Drug" linkID="36492"&gt;Ro-63-9141&lt;/ulink&gt; and MC-02479 have shown in vivo and in vitro activity against strains of MRSA, enterococci and PRSpn. &lt;ulink linkType="Drug" linkID="36492"&gt;Ro-63-9141&lt;/ulink&gt; has additional activity against aerobic and non-fermenting Gram-negative bacteria. Treatment of experimental infections with MRSA in rats demonstrated that &lt;ulink linkType="Drug" linkID="36492"&gt;Ro-63-9141&lt;/ulink&gt; was as effective as standard therapy. &lt;/para&gt;&lt;para&gt;Although in vivo data about the efficacy of &lt;ulink linkType="Drug" linkID="36492"&gt;Ro-63-9141&lt;/ulink&gt; in experimental infections are scarce, this antibiotic remains a promising compound for the treatment of infections caused by resistant Gram-positive organisms (especially MRSA) and various Gram-negative bacteria. However, its further development will depend on the attributes of other cephalosporins of this new generation, its efficacy and safety profile in clinical trials, as well as a willing licensee. &lt;br/&gt;&lt;/para&gt;</ExpertReview><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="18607">Correvio Pharma Corp</Company><Country id="IT">Italy</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1815">Bacterial pneumonia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-12-31T00:00:00.000Z</StatusDate><Source id="2008403" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18607">Correvio Pharma Corp</Company><Country id="DE">Germany</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1815">Bacterial pneumonia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-12-31T00:00:00.000Z</StatusDate><Source id="2008403" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1149364">Avir Pharma Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1815">Bacterial pneumonia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-04-09T00:00:00.000Z</StatusDate><Source id="2020325" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1022379">Hikma Pharmaceuticals plc</Company><Country id="SA">Saudi Arabia</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1815">Bacterial pneumonia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-05-15T00:00:00.000Z</StatusDate><Source id="2033845" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1074739">Unimedic AB</Company><Country id="XQ">Nordic countries</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1815">Bacterial pneumonia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-12-31T00:00:00.000Z</StatusDate><Source id="2008403" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18607">Correvio Pharma Corp</Company><Country id="FR">France</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1815">Bacterial pneumonia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-12-31T00:00:00.000Z</StatusDate><Source id="2008403" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18607">Correvio Pharma Corp</Company><Country id="ES">Spain</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1815">Bacterial pneumonia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-05-08T00:00:00.000Z</StatusDate><Source id="2034219" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18607">Correvio Pharma Corp</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1815">Bacterial pneumonia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-12-31T00:00:00.000Z</StatusDate><Source id="2008403" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18607">Correvio Pharma Corp</Company><Country id="AT">Austria</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1815">Bacterial pneumonia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-12-31T00:00:00.000Z</StatusDate><Source id="2008403" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1063950">Biotoscana International</Company><Country id="AR">Argentina</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1815">Bacterial pneumonia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-03-06T00:00:00.000Z</StatusDate><Source id="2010630" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1063950">Biotoscana International</Company><Country id="PE">Peru</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1815">Bacterial pneumonia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2019-03-31T00:00:00.000Z</StatusDate><Source id="2136234" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18607">Correvio Pharma Corp</Company><Country id="GB">UK</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1815">Bacterial pneumonia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-12-31T00:00:00.000Z</StatusDate><Source id="2008403" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="28104">Basilea Pharmaceutica International Ltd</Company><Country id="AU">Australia</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1815">Bacterial pneumonia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-11-10T00:00:00.000Z</StatusDate><Source id="1736265" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18607">Correvio Pharma Corp</Company><Country id="LU">Luxembourg</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1815">Bacterial pneumonia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-12-31T00:00:00.000Z</StatusDate><Source id="2008403" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18607">Correvio Pharma Corp</Company><Country id="BE">Belgium</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1815">Bacterial pneumonia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-12-31T00:00:00.000Z</StatusDate><Source id="2008403" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18607">Correvio Pharma Corp</Company><Country id="IE">Ireland</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1815">Bacterial pneumonia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-12-31T00:00:00.000Z</StatusDate><Source id="2015656" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1032662">Shenzhen Gosun Pharmaceutical Co Ltd</Company><Country id="CN">China</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="485">Bacterial skin infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-12-27T00:00:00.000Z</StatusDate><Source id="2100481" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="28104">Basilea Pharmaceutica International Ltd</Company><Country id="CN">China</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="485">Bacterial skin infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-12-27T00:00:00.000Z</StatusDate><Source id="2100481" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1168485">Patheon UK Ltd</Company><Country id="CN">China</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="485">Bacterial skin infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-12-27T00:00:00.000Z</StatusDate><Source id="2100481" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="28104">Basilea Pharmaceutica International Ltd</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3779">Infectious endocarditis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-06-01T00:00:00.000Z</StatusDate><Source id="2145763" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="28104">Basilea Pharmaceutica International Ltd</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="485">Bacterial skin infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2005-02-03T00:00:00.000Z</StatusDate><Source id="583424" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="28104">Basilea Pharmaceutica International Ltd</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3779">Infectious endocarditis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-06-01T00:00:00.000Z</StatusDate><Source id="2145763" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="28104">Basilea Pharmaceutica International Ltd</Company><Country id="IL">Israel</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3779">Infectious endocarditis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-06-01T00:00:00.000Z</StatusDate><Source id="2145763" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="28104">Basilea Pharmaceutica International Ltd</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="308">Staphylococcus aureus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-06-01T00:00:00.000Z</StatusDate><Source id="2145763" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="28104">Basilea Pharmaceutica International Ltd</Company><Country id="IL">Israel</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="308">Staphylococcus aureus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-06-01T00:00:00.000Z</StatusDate><Source id="2145763" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="28104">Basilea Pharmaceutica International Ltd</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="308">Staphylococcus aureus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-06-01T00:00:00.000Z</StatusDate><Source id="2145763" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1022379">Hikma Pharmaceuticals plc</Company><Country id="XC">North Africa</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1815">Bacterial pneumonia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-10-15T00:00:00.000Z</StatusDate><Source id="1703539" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1063950">Biotoscana International</Company><Country id="BR">Brazil</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1815">Bacterial pneumonia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-09-13T00:00:00.000Z</StatusDate><Source id="1795574" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18607">Correvio Pharma Corp</Company><Country id="IL">Israel</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1815">Bacterial pneumonia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-09-12T00:00:00.000Z</StatusDate><Source id="1961032" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1063950">Biotoscana International</Company><Country id="MX">Mexico</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1815">Bacterial pneumonia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-09-13T00:00:00.000Z</StatusDate><Source id="1795574" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1022379">Hikma Pharmaceuticals plc</Company><Country id="XJ">Middle East</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1815">Bacterial pneumonia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-10-15T00:00:00.000Z</StatusDate><Source id="1703539" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1032662">Shenzhen Gosun Pharmaceutical Co Ltd</Company><Country id="HK">Hong Kong</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="485">Bacterial skin infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-09-28T00:00:00.000Z</StatusDate><Source id="1965963" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1032662">Shenzhen Gosun Pharmaceutical Co Ltd</Company><Country id="MO">Macau</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="485">Bacterial skin infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-09-28T00:00:00.000Z</StatusDate><Source id="1965963" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1063950">Biotoscana International</Company><Country id="CO">Colombia</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1815">Bacterial pneumonia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-09-13T00:00:00.000Z</StatusDate><Source id="1795574" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17332">Johnson &amp; Johnson</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="W" sortOrder="5">Withdrawn</DevelopmentStatus><Indication id="790">Diabetic foot ulcer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2010-09-17T00:00:00.000Z</StatusDate><Source id="1129434" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17332">Johnson &amp; Johnson</Company><Country id="CA">Canada</Country><DevelopmentStatus id="W" sortOrder="5">Withdrawn</DevelopmentStatus><Indication id="485">Bacterial skin infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2010-04-09T00:00:00.000Z</StatusDate><Source id="1089203" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17332">Johnson &amp; Johnson</Company><Country id="AZ">Azerbaijan</Country><DevelopmentStatus id="W" sortOrder="5">Withdrawn</DevelopmentStatus><Indication id="485">Bacterial skin infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2010-09-17T00:00:00.000Z</StatusDate><Source id="1129434" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="28104">Basilea Pharmaceutica International Ltd</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="W" sortOrder="5">Withdrawn</DevelopmentStatus><Indication id="1267">MRSA infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2010-09-17T00:00:00.000Z</StatusDate><Source id="1129434" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17332">Johnson &amp; Johnson</Company><Country id="UA">Ukraine</Country><DevelopmentStatus id="W" sortOrder="5">Withdrawn</DevelopmentStatus><Indication id="485">Bacterial skin infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2010-09-17T00:00:00.000Z</StatusDate><Source id="1129434" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="28104">Basilea Pharmaceutica International Ltd</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="W" sortOrder="5">Withdrawn</DevelopmentStatus><Indication id="485">Bacterial skin infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2010-09-17T00:00:00.000Z</StatusDate><Source id="1129434" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="28104">Basilea Pharmaceutica International Ltd</Company><Country id="CA">Canada</Country><DevelopmentStatus id="W" sortOrder="5">Withdrawn</DevelopmentStatus><Indication id="485">Bacterial skin infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2010-04-09T00:00:00.000Z</StatusDate><Source id="1089203" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17332">Johnson &amp; Johnson</Company><Country id="RU">Russian Federation</Country><DevelopmentStatus id="W" sortOrder="5">Withdrawn</DevelopmentStatus><Indication id="485">Bacterial skin infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2010-09-17T00:00:00.000Z</StatusDate><Source id="1129434" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17332">Johnson &amp; Johnson</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="W" sortOrder="5">Withdrawn</DevelopmentStatus><Indication id="485">Bacterial skin infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2010-09-17T00:00:00.000Z</StatusDate><Source id="1129434" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="28104">Basilea Pharmaceutica International Ltd</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="W" sortOrder="5">Withdrawn</DevelopmentStatus><Indication id="790">Diabetic foot ulcer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2010-09-17T00:00:00.000Z</StatusDate><Source id="1129434" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17332">Johnson &amp; Johnson</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="W" sortOrder="5">Withdrawn</DevelopmentStatus><Indication id="1267">MRSA infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2010-09-17T00:00:00.000Z</StatusDate><Source id="1129434" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17332">Johnson &amp; Johnson</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="485">Bacterial skin infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-02-28T00:00:00.000Z</StatusDate><Source id="1167274" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17332">Johnson &amp; Johnson</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="790">Diabetic foot ulcer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-02-28T00:00:00.000Z</StatusDate><Source id="1167274" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17332">Johnson &amp; Johnson</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="1815">Bacterial pneumonia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-02-28T00:00:00.000Z</StatusDate><Source id="1167274" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17332">Johnson &amp; Johnson</Company><Country id="AU">Australia</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="485">Bacterial skin infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-02-28T00:00:00.000Z</StatusDate><Source id="1167274" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17332">Johnson &amp; Johnson</Company><Country id="HK">Hong Kong</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="485">Bacterial skin infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-02-28T00:00:00.000Z</StatusDate><Source id="1167274" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17332">Johnson &amp; Johnson</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="1267">MRSA infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-02-28T00:00:00.000Z</StatusDate><Source id="1167274" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17332">Johnson &amp; Johnson</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="1267">MRSA infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-02-28T00:00:00.000Z</StatusDate><Source id="1167274" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17332">Johnson &amp; Johnson</Company><Country id="AU">Australia</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="790">Diabetic foot ulcer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-02-28T00:00:00.000Z</StatusDate><Source id="1167274" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17332">Johnson &amp; Johnson</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="485">Bacterial skin infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-02-28T00:00:00.000Z</StatusDate><Source id="1167274" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="26178">F Hoffmann-La Roche AG</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="5">Other</DiscontinuedReason><Indication id="40">Bacterial infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2000-05-15T00:00:00.000Z</StatusDate><Source id="364336" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17332">Johnson &amp; Johnson</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="1815">Bacterial pneumonia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-02-28T00:00:00.000Z</StatusDate><Source id="1167274" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="28104">Basilea Pharmaceutica International Ltd</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="1815">Bacterial pneumonia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-03-31T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="28104">Basilea Pharmaceutica International Ltd</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="1267">MRSA infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2009-03-31T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="28104">Basilea Pharmaceutica International Ltd</Company><Country id="CA">Canada</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="1815">Bacterial pneumonia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-06-14T00:00:00.000Z</StatusDate><Source id="1937741" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="28104">Basilea Pharmaceutica International Ltd</Company><Country id="DK">Denmark</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="1815">Bacterial pneumonia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-09-20T00:00:00.000Z</StatusDate><Source id="1797653" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="28104">Basilea Pharmaceutica International Ltd</Company><Country id="SA">Saudi Arabia</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="1815">Bacterial pneumonia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-10-15T00:00:00.000Z</StatusDate><Source id="1703539" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="28104">Basilea Pharmaceutica International Ltd</Company><Country id="FI">Finland</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="1815">Bacterial pneumonia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-09-20T00:00:00.000Z</StatusDate><Source id="1797653" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="28104">Basilea Pharmaceutica International Ltd</Company><Country id="SE">Sweden</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="1815">Bacterial pneumonia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-09-20T00:00:00.000Z</StatusDate><Source id="1797653" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="28104">Basilea Pharmaceutica International Ltd</Company><Country id="NO">Norway</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="1815">Bacterial pneumonia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-09-20T00:00:00.000Z</StatusDate><Source id="1797653" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="28104">Basilea Pharmaceutica International Ltd</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1815">Bacterial pneumonia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2005-04-08T00:00:00.000Z</StatusDate><Source id="594842" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28104">Basilea Pharmaceutica International Ltd</Company><Country id="EU">EU</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="485">Bacterial skin infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2007-06-18T00:00:00.000Z</StatusDate><Source id="805391" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28104">Basilea Pharmaceutica International Ltd</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="485">Bacterial skin infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2004-11-04T00:00:00.000Z</StatusDate><Source id="569097" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28104">Basilea Pharmaceutica International Ltd</Company><Country id="EU">EU</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="790">Diabetic foot ulcer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2007-06-18T00:00:00.000Z</StatusDate><Source id="805391" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28104">Basilea Pharmaceutica International Ltd</Company><Country id="EU">EU</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="313">Streptococcus pneumoniae infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2012-07-30T00:00:00.000Z</StatusDate><Source id="1311757" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28104">Basilea Pharmaceutica International Ltd</Company><Country id="EU">EU</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="1815">Bacterial pneumonia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2012-07-30T00:00:00.000Z</StatusDate><Source id="1311757" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28104">Basilea Pharmaceutica International Ltd</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="1815">Bacterial pneumonia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2013-09-16T00:00:00.000Z</StatusDate><Source id="1477276" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28104">Basilea Pharmaceutica International Ltd</Company><Country id="IT">Italy</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1815">Bacterial pneumonia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2014-10-31T00:00:00.000Z</StatusDate><Source id="1607219" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28104">Basilea Pharmaceutica International Ltd</Company><Country id="FR">France</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1815">Bacterial pneumonia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2014-10-31T00:00:00.000Z</StatusDate><Source id="1607219" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28104">Basilea Pharmaceutica International Ltd</Company><Country id="GB">UK</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1815">Bacterial pneumonia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2014-10-31T00:00:00.000Z</StatusDate><Source id="1607219" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28104">Basilea Pharmaceutica International Ltd</Company><Country id="AT">Austria</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1815">Bacterial pneumonia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2014-10-31T00:00:00.000Z</StatusDate><Source id="1607219" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28104">Basilea Pharmaceutica International Ltd</Company><Country id="EU">EU</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1815">Bacterial pneumonia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2013-10-23T00:00:00.000Z</StatusDate><Source id="1504454" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28104">Basilea Pharmaceutica International Ltd</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1815">Bacterial pneumonia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2014-12-22T00:00:00.000Z</StatusDate><Source id="1622429" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28104">Basilea Pharmaceutica International Ltd</Company><Country id="NO">Norway</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1815">Bacterial pneumonia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2014-10-31T00:00:00.000Z</StatusDate><Source id="1607219" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28104">Basilea Pharmaceutica International Ltd</Company><Country id="DK">Denmark</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1815">Bacterial pneumonia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2014-10-31T00:00:00.000Z</StatusDate><Source id="1607219" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28104">Basilea Pharmaceutica International Ltd</Company><Country id="FI">Finland</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1815">Bacterial pneumonia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2014-10-31T00:00:00.000Z</StatusDate><Source id="1607219" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28104">Basilea Pharmaceutica International Ltd</Company><Country id="EU">EU</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="313">Streptococcus pneumoniae infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2013-10-23T00:00:00.000Z</StatusDate><Source id="1504454" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28104">Basilea Pharmaceutica International Ltd</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1267">MRSA infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2007-06-18T00:00:00.000Z</StatusDate><Source id="805391" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28104">Basilea Pharmaceutica International Ltd</Company><Country id="CA">Canada</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1815">Bacterial pneumonia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-10-12T00:00:00.000Z</StatusDate><Source id="1702266" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28104">Basilea Pharmaceutica International Ltd</Company><Country id="SE">Sweden</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1815">Bacterial pneumonia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2014-10-31T00:00:00.000Z</StatusDate><Source id="1607219" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28104">Basilea Pharmaceutica International Ltd</Company><Country id="CN">China</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="485">Bacterial skin infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2014-01-21T00:00:00.000Z</StatusDate><Source id="1517757" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1074739">Unimedic AB</Company><Country id="NO">Norway</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1815">Bacterial pneumonia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-09-20T00:00:00.000Z</StatusDate><Source id="1797653" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1074739">Unimedic AB</Company><Country id="DK">Denmark</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1815">Bacterial pneumonia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-09-20T00:00:00.000Z</StatusDate><Source id="1797653" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1074739">Unimedic AB</Company><Country id="SE">Sweden</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1815">Bacterial pneumonia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-09-20T00:00:00.000Z</StatusDate><Source id="1797653" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1074739">Unimedic AB</Company><Country id="FI">Finland</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1815">Bacterial pneumonia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-09-20T00:00:00.000Z</StatusDate><Source id="1797653" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1063950">Biotoscana International</Company><Country id="AR">Argentina</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1815">Bacterial pneumonia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-09-13T00:00:00.000Z</StatusDate><Source id="1795574" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1063950">Biotoscana International</Company><Country id="AR">Argentina</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1815">Bacterial pneumonia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-12-31T00:00:00.000Z</StatusDate><Source id="2015656" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1149364">Avir Pharma Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1815">Bacterial pneumonia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-06-14T00:00:00.000Z</StatusDate><Source id="1937741" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18607">Correvio Pharma Corp</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1815">Bacterial pneumonia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-09-12T00:00:00.000Z</StatusDate><Source id="1961032" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28104">Basilea Pharmaceutica International Ltd</Company><Country id="GB">UK</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1815">Bacterial pneumonia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-03-01T00:00:00.000Z</StatusDate><Source id="1641414" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28104">Basilea Pharmaceutica International Ltd</Company><Country id="DE">Germany</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1815">Bacterial pneumonia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2014-12-05T00:00:00.000Z</StatusDate><Source id="1618635" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28104">Basilea Pharmaceutica International Ltd</Company><Country id="FR">France</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1815">Bacterial pneumonia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-03-01T00:00:00.000Z</StatusDate><Source id="1641414" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28104">Basilea Pharmaceutica International Ltd</Company><Country id="IT">Italy</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1815">Bacterial pneumonia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-03-01T00:00:00.000Z</StatusDate><Source id="1641414" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28104">Basilea Pharmaceutica International Ltd</Company><Country id="AT">Austria</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1815">Bacterial pneumonia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-06-23T00:00:00.000Z</StatusDate><Source id="1672179" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28104">Basilea Pharmaceutica International Ltd</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1815">Bacterial pneumonia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-08-15T00:00:00.000Z</StatusDate><Source id="1788011" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28104">Basilea Pharmaceutica International Ltd</Company><Country id="ES">Spain</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1815">Bacterial pneumonia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2014-10-31T00:00:00.000Z</StatusDate><Source id="1607219" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28104">Basilea Pharmaceutica International Ltd</Company><Country id="LU">Luxembourg</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1815">Bacterial pneumonia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2014-10-31T00:00:00.000Z</StatusDate><Source id="1607219" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28104">Basilea Pharmaceutica International Ltd</Company><Country id="BE">Belgium</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1815">Bacterial pneumonia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2014-10-31T00:00:00.000Z</StatusDate><Source id="1607219" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18607">Correvio Pharma Corp</Company><Country id="ES">Spain</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1815">Bacterial pneumonia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-12-31T00:00:00.000Z</StatusDate><Source id="2008403" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1022379">Hikma Pharmaceuticals plc</Company><Country id="SA">Saudi Arabia</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1815">Bacterial pneumonia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-12-31T00:00:00.000Z</StatusDate><Source id="2015656" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28104">Basilea Pharmaceutica International Ltd</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1267">MRSA infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2007-06-18T00:00:00.000Z</StatusDate><Source id="805391" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28104">Basilea Pharmaceutica International Ltd</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1815">Bacterial pneumonia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2005-04-08T00:00:00.000Z</StatusDate><Source id="594842" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1032662">Shenzhen Gosun Pharmaceutical Co Ltd</Company><Country id="CN">China</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="485">Bacterial skin infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-09-28T00:00:00.000Z</StatusDate><Source id="1965963" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28104">Basilea Pharmaceutica International Ltd</Company><Country id="CN">China</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="485">Bacterial skin infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-09-28T00:00:00.000Z</StatusDate><Source id="1965963" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1063950">Biotoscana International</Company><Country id="PE">Peru</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1815">Bacterial pneumonia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-08-14T00:00:00.000Z</StatusDate><Source id="2063306" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28104">Basilea Pharmaceutica International Ltd</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="3779">Infectious endocarditis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-04-21T00:00:00.000Z</StatusDate><Source id="1919479" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28104">Basilea Pharmaceutica International Ltd</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="308">Staphylococcus aureus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-04-21T00:00:00.000Z</StatusDate><Source id="1919479" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28104">Basilea Pharmaceutica International Ltd</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="485">Bacterial skin infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2003-03-10T00:00:00.000Z</StatusDate><Source id="481324" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="26178">F Hoffmann-La Roche AG</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="40">Bacterial infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1998-09-15T00:00:00.000Z</StatusDate><Source id="298361" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28104">Basilea Pharmaceutica International Ltd</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="40">Bacterial infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2001-10-22T00:00:00.000Z</StatusDate><Source id="481324" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17332">Johnson &amp; Johnson</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="485">Bacterial skin infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2005-02-03T00:00:00.000Z</StatusDate><Source id="583424" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28104">Basilea Pharmaceutica International Ltd</Company><Country id="CA">Canada</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="485">Bacterial skin infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2007-07-17T00:00:00.000Z</StatusDate><Source id="813560" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17332">Johnson &amp; Johnson</Company><Country id="CA">Canada</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="485">Bacterial skin infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2007-07-17T00:00:00.000Z</StatusDate><Source id="813560" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17332">Johnson &amp; Johnson</Company><Country id="CA">Canada</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="485">Bacterial skin infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2008-06-30T00:00:00.000Z</StatusDate><Source id="921274" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28104">Basilea Pharmaceutica International Ltd</Company><Country id="CA">Canada</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="485">Bacterial skin infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2008-06-30T00:00:00.000Z</StatusDate><Source id="921274" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17332">Johnson &amp; Johnson</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="40">Bacterial infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2007-09-30T00:00:00.000Z</StatusDate><Source id="830686" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17332">Johnson &amp; Johnson</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="485">Bacterial skin infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2007-06-18T00:00:00.000Z</StatusDate><Source id="805391" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28104">Basilea Pharmaceutica International Ltd</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="485">Bacterial skin infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2007-06-18T00:00:00.000Z</StatusDate><Source id="805391" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28104">Basilea Pharmaceutica International Ltd</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="485">Bacterial skin infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2008-11-12T00:00:00.000Z</StatusDate><Source id="962759" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17332">Johnson &amp; Johnson</Company><Country id="UA">Ukraine</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="485">Bacterial skin infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2008-12-31T00:00:00.000Z</StatusDate><Source id="986204" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17332">Johnson &amp; Johnson</Company><Country id="CA">Canada</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="485">Bacterial skin infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2008-09-08T00:00:00.000Z</StatusDate><Source id="941318" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28104">Basilea Pharmaceutica International Ltd</Company><Country id="CA">Canada</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="485">Bacterial skin infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2008-08-31T00:00:00.000Z</StatusDate><Source id="1074945" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28104">Basilea Pharmaceutica International Ltd</Company><Country id="US">US</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="790">Diabetic foot ulcer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2007-05-18T00:00:00.000Z</StatusDate><Source id="796632" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17332">Johnson &amp; Johnson</Company><Country id="US">US</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="790">Diabetic foot ulcer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2007-05-18T00:00:00.000Z</StatusDate><Source id="796632" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28104">Basilea Pharmaceutica International Ltd</Company><Country id="US">US</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="485">Bacterial skin infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2007-05-18T00:00:00.000Z</StatusDate><Source id="796632" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17332">Johnson &amp; Johnson</Company><Country id="US">US</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="485">Bacterial skin infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2007-05-18T00:00:00.000Z</StatusDate><Source id="796632" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28104">Basilea Pharmaceutica International Ltd</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1267">MRSA infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2009-02-24T00:00:00.000Z</StatusDate><Source id="986215" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28104">Basilea Pharmaceutica International Ltd</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="485">Bacterial skin infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2009-02-24T00:00:00.000Z</StatusDate><Source id="986215" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28104">Basilea Pharmaceutica International Ltd</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="790">Diabetic foot ulcer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2009-02-24T00:00:00.000Z</StatusDate><Source id="986215" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17332">Johnson &amp; Johnson</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1267">MRSA infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2009-02-24T00:00:00.000Z</StatusDate><Source id="986215" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17332">Johnson &amp; Johnson</Company><Country id="AZ">Azerbaijan</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="485">Bacterial skin infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2009-12-30T00:00:00.000Z</StatusDate><Source id="1065953" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17332">Johnson &amp; Johnson</Company><Country id="RU">Russian Federation</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="485">Bacterial skin infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2009-12-30T00:00:00.000Z</StatusDate><Source id="1065953" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17332">Johnson &amp; Johnson</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="485">Bacterial skin infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2009-02-24T00:00:00.000Z</StatusDate><Source id="986215" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17332">Johnson &amp; Johnson</Company><Country id="UA">Ukraine</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="485">Bacterial skin infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2009-04-30T00:00:00.000Z</StatusDate><Source id="1004851" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17332">Johnson &amp; Johnson</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="790">Diabetic foot ulcer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2009-02-24T00:00:00.000Z</StatusDate><Source id="986215" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17332">Johnson &amp; Johnson</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1267">MRSA infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2007-06-18T00:00:00.000Z</StatusDate><Source id="805391" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17332">Johnson &amp; Johnson</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1267">MRSA infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2007-06-18T00:00:00.000Z</StatusDate><Source id="805391" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17332">Johnson &amp; Johnson</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1815">Bacterial pneumonia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2005-04-08T00:00:00.000Z</StatusDate><Source id="594842" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17332">Johnson &amp; Johnson</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1815">Bacterial pneumonia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2005-04-08T00:00:00.000Z</StatusDate><Source id="594842" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17332">Johnson &amp; Johnson</Company><Country id="AU">Australia</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="485">Bacterial skin infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2007-10-08T00:00:00.000Z</StatusDate><Source id="837122" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17332">Johnson &amp; Johnson</Company><Country id="HK">Hong Kong</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="485">Bacterial skin infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2009-12-30T00:00:00.000Z</StatusDate><Source id="1065953" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17332">Johnson &amp; Johnson</Company><Country id="EU">EU</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="485">Bacterial skin infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2007-06-18T00:00:00.000Z</StatusDate><Source id="805391" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17332">Johnson &amp; Johnson</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="485">Bacterial skin infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2005-02-03T00:00:00.000Z</StatusDate><Source id="583424" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17332">Johnson &amp; Johnson</Company><Country id="EU">EU</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="790">Diabetic foot ulcer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2007-06-18T00:00:00.000Z</StatusDate><Source id="805391" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17332">Johnson &amp; Johnson</Company><Country id="AU">Australia</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="790">Diabetic foot ulcer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2007-10-08T00:00:00.000Z</StatusDate><Source id="837122" type="PR"></Source></DevelopmentStatusHistoric></IDdbDevelopmentStatus><RegulatoryDesignationStatus><Row><RegulatoryDesignation id="2">Fast Track</RegulatoryDesignation><OwnerCompany id="28104">Basilea Pharmaceutica International Ltd</OwnerCompany><Country id="US">US</Country><Indication id="360">Pneumonia</Indication><AwardedIndication>Pneumonia</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2005-08-24T00:00:00.000Z</MileStoneDate><Source id="619554" type="PR"></Source></Row><Row><RegulatoryDesignation id="2">Fast Track</RegulatoryDesignation><OwnerCompany id="28104">Basilea Pharmaceutica International Ltd</OwnerCompany><Country id="US">US</Country><Indication id="485">Bacterial skin infection</Indication><AwardedIndication>Treatment of complicated skin and skin structure infections, including diabetic foot infections</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2003-03-10T00:00:00.000Z</MileStoneDate><Source id="481324" type="PR"></Source></Row><Row><RegulatoryDesignation id="12">Qualified Infectious Disease Product</RegulatoryDesignation><OwnerCompany id="28104">Basilea Pharmaceutica International Ltd</OwnerCompany><Country id="US">US</Country><Indication id="40">Bacterial infection</Indication><AwardedIndication>Treatment of bacterial bloodstream infections caused by Staphylococcus aureus</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-12-21T00:00:00.000Z</MileStoneDate><Source id="1993143" type="PR"></Source></Row><Row><RegulatoryDesignation id="12">Qualified Infectious Disease Product</RegulatoryDesignation><OwnerCompany id="28104">Basilea Pharmaceutica International Ltd</OwnerCompany><Country id="US">US</Country><Indication id="360">Pneumonia</Indication><AwardedIndication>Community-acquired pneumonia</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-08-12T00:00:00.000Z</MileStoneDate><Source id="1685781" type="PR"></Source></Row></RegulatoryDesignationStatus><Targets><Target id="PTGT-11672"><Name>Penicillin binding protein</Name><SwissprotNumbers></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Reference Added</Reason><Description>1 reference added [&lt;ulink url="utility.reference?i_reference_id=2149224" linkType="reference" linkID="2149224"&gt;2149224&lt;/ulink&gt;]
							</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1022379">Hikma Pharmaceuticals plc</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="1032662">Shenzhen Gosun Pharmaceutical Co Ltd</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="1063950">Biotoscana International</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="1074739">Unimedic AB</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="1101929">IQVIA Holdings Inc</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="1149364">Avir Pharma Inc</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="17332">Johnson &amp; Johnson</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>1</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="18607">Correvio Pharma Corp</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="20516">US Government</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="28104">Basilea Pharmaceutica International Ltd</Company><CountAsPrincipalActive>2</CountAsPrincipalActive><CountAsPrincipalInactive>1</CountAsPrincipalInactive><CountAsPartnerActive>2</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>10</CountTotal></Company><Company><Company id="30992">Patheon Pharmaceuticals Inc</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="13">Drug - Funding</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type><Type><Type sortOrder="4">Drug - Development/Commercialization License</Type><CountActive>2</CountActive><CountInactive>1</CountInactive><CountTotal>3</CountTotal></Type><Type><Type sortOrder="5">Drug - Commercialization License</Type><CountActive>4</CountActive><CountInactive>0</CountInactive><CountTotal>4</CountTotal></Type><Type><Type sortOrder="6">Drug - Manufacturing/Supply</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type><Type><Type sortOrder="7">Drug - Development Services</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><StructureSmiles><Smiles>Cc1c(oc(=O)o1)COC(=O)N2CC[C@H](C2)N3CC/C(=C\C4=C(N5[C@@H]([C@@H](C5=O)NC(=O)/C(=N\O)/c6nc(sn6)N)SC4)C(=O)O)/C3=O</Smiles><Smiles>C1CNC[C@@H]1N2CC/C(=C\C3=C(N4[C@@H]([C@@H](C4=O)NC(=O)/C(=N\O)/c5nc(sn5)N)SC3)C(=O)O)/C2=O</Smiles><Smiles>Cc1c(oc(=O)o1)COC(=O)N2CC[C@H](C2)N3CC/C(=C\C4=C(N5[C@@H]([C@@H](C5=O)NC(=O)/C(=N\O)/c6nc(sn6)N)SC4)C(=O)[O-])/C3=O.[Na+]</Smiles></StructureSmiles><Deals><Deal id="107643" title="Cilag to codevelop Basilea's ceftobiprole worldwide  "></Deal><Deal id="150155" title="Quintiles to provide commercial services for Basilea's ceftobiprole medocaril in Europe"></Deal><Deal id="156766" title="Hikma to distribute and market Basilea's Zevtera and isavuconazole in MENA     "></Deal><Deal id="160023" title="BARDA to award Basilea funding for the phase III clinical development of ceftobiprole against bacterial infections"></Deal><Deal id="162254" title="Biotoscana to supply, distribute and commercialize Basilea's isavuconazole and ceftobiprole in several Latin America countries  "></Deal><Deal id="162371" title="Unimedic to commercialize Basilea's isavuconazole and ceftobiprole in Sweden, Finland, Denmark and Norway   "></Deal><Deal id="240695" title="Avir to distribute Basilea's Cresemba and Zevtera in Canada"></Deal><Deal id="242566" title="Cardiome to distribute Basilea's ceftobiprole in Europe and Israel                  "></Deal><Deal id="242989" title="CR Gosun to develop and commercialize Basilea's Zevtera in China, Hong Kong and Macao       "></Deal><Deal id="252694" title="Patheon to manufacture Basilea's ceftobiprole medocaril against pneumonia in China "></Deal></Deals><PatentFamilies><PatentFamily id="1329885" number="WO-2010136422" title="Method for the production of ceftobiprole medocaril"></PatentFamily><PatentFamily id="1448618" number="WO-2009051626" title="Cephalosporin derivative formulation"></PatentFamily><PatentFamily id="1531138" number="WO-2006050631" title="Stabilized freeze-dried formulation for cephalosporin derivatives"></PatentFamily><PatentFamily id="1670796" number="WO-00190111" title="New process for the preparation of vinyl-pyrrolidinone cephalosporine derivatives"></PatentFamily><PatentFamily id="172082" number="WO-09965920" title="Derivatives of 3-(2-oxo-[1,3']bipyrrolidinyl-3-ylidenemethyl)-cephems"></PatentFamily><PatentFamily id="1783239" number="WO-2010072672" title="New crystal polymorphs of ceftobiprole"></PatentFamily><PatentFamily id="223878" number="TW-200835523" title="Cephalosporin derivative formulation"></PatentFamily><PatentFamily id="2275688" number="EP-00911030" title="Antimicrobial composition comprising a vinyl pyrrolidinone derivative and a carbapenem antibiotic or a beta-lactamase inhibitor"></PatentFamily><PatentFamily id="2299270" number="WO-2011141415" title="Oxidation process for preparing 3-formyl-cephem derivatives"></PatentFamily><PatentFamily id="2371335" number="WO-2009127623" title="Crystalline (6R,7R)-7-{2-(5-amino-[1,2,4]thiadiazol-3-yl)-2-[(Z)-trityloxyimino]-acetylamino}-3-[(R)-1'-tert-butoxycarbonyl-2-oxo-[1,3']bipyrrolidinyl-(3E)-ylidenemethyl]-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid benzhydryl ester; its manufacture and use"></PatentFamily><PatentFamily id="2639658" number="CN-103275104" title="Manufacturing method for ceftobiprole head and head spore ceftobiprole ester"></PatentFamily><PatentFamily id="429795" number="WO-2004013097" title="Process for the preparation of amino-pyrrolidine derivatives"></PatentFamily><PatentFamily id="844564" number="WO-2004085444" title="Cephalosporin in crystalline form"></PatentFamily></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="10">Process</Type><Count>4</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="11">Process (Intermediate)</Type><Count>3</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="13">Product (derivative)</Type><Count>2</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="3">Component of Combination</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="5">Formulation</Type><Count>3</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Hikma Pharmaceuticals plc" id="1022379"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Suzhou MiracPharma Technology Co Ltd" id="1095700"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Johnson &amp; Johnson" id="17332"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Roche Holding AG" id="19446"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Individual" id="21144"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Novartis AG" id="23137"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Basilea Pharmaceutica International Ltd" id="28104"></CompanyLink><CountAsOwner>9</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>9</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>Y</hasSWOTs></ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordOutput>